

# ARTHRITIS & RHEUMATISM

---

OFFICIAL JOURNAL OF THE AMERICAN RHEUMATISM ASSOCIATION  
SECTION OF THE ARTHRITIS FOUNDATION

---

## CONTENTS VOLUME 19, 1976

VOL. 19

JANUARY-FEBRUARY

No. 1

Electron Microscopic Observations of Immunoreactive Cells in the Rheumatoid Synovial Membrane <i>Hitoshi Ishikawa and Morris Ziff</i> .....	1
Cutaneous Vessel Immune Deposits in Rheumatoid Arthritis <i>Doyt L. Conn, Arnold L. Schroeter, and Frederic C. McDuffie</i> .....	15
Treatment of Psoriatic Arthritis with Azaribine <i>Seymour Levine and Harold E. Paulus</i> .....	21
Presidential Address: Whither or Wither <i>Lawrence E. Shulman</i> .....	29
Specific Detection and Semiquantitation of Microorganisms in Tissue by Nucleic Acid Hybridization <i>Charles R. Steinman and Konrad Hsu</i> .....	38
Therapeutic Studies in NZB/W Mice <i>Michael C. Gelfand, Peter H. Schur, Richard Asofsky, and Alfred D. Steinberg</i> .....	43
Cyclophosphamide Protection in NZB/NZW Disease <i>Alan D. Morris, James Esterly, Gerald Chase, and Gordon C. Sharp</i> .....	49
Current Comment: Geographic Distribution of Consultant Rheumatologists in the United States—1975 <i>Daniel J. McCarty</i> .....	56
Experimental Hemarthrosis in the Knee of the Mature Canine <i>F. Richard Convery, Savio L-Y Woo, Wayne H. Akeson, David Amiel, and Lawrence L. Malcom</i> .....	59
Current Comment: Recent Insights into the Pathogenesis of the Proliferative Lesion in Rheumatoid Arthritis <i>Edward Day Harris, Jr.</i> .....	68
Reduction of Phagocytosis and Lysosomal Enzyme Release from Human Leukocytes by Serum from Patients with Systemic Lupus Erythematosus <i>Robert B. Zurier</i> .....	73
Absent Factor II in Systemic Lupus Erythematosus <i>Ethan A. Natelson, Gerald S. Cyprus, and Robert A. Hettig</i> .....	79
Dermatoglyphic Study of Systemic Lupus Erythematosus <i>Robert W. Dubois, John M. Weiner, and Edmund L. Dubois</i> .....	83
Lymphocyte Responsiveness in Systemic Lupus Erythematosus <i>Peter D. Utsinger</i> .....	88
Crystal Shedding and Acute Pseudogout <i>Robert M. Bennett, James R. Lehr, and Daniel J. McCarty</i> .....	93

Hemarthrosis Associated with Sodium Warfarin Therapy <i>James H. Wild and Nathan J. Zvaifler</i> .....	98
Cryoglobulinemia in Felty's Syndrome <i>Michael Weisman and Nathan J. Zvaifler</i> .....	103
Coexistence of Ankylosing Spondylitis and Rheumatoid Arthritis <i>Harvinder S. Luthra, Richard H. Ferguson, and Doyt L. Conn</i> .....	111
Correlations Between Transaminase Concentrations and Serum Salicylate Concentration in Juvenile Rheumatoid Arthritis <i>John J. Miller III and David B. Weissman</i> .....	115
Perforation of Nasal Septum in Rheumatic Diseases <i>Robert F. Willkens, Gilbert J. Roth, Alvin Novak, and Joseph W. Walike</i> .....	119
Letters, Book Reviews .....	122
ARA Announcements .....	128

**VOL. 19**

**MARCH-APRIL**

**No. 2**

Histocompatibility Antigens in Systemic Lupus Erythematosus <i>Marc A. Goldberg, Frank C. Arnett, Wilma B. Bias, and Lawrence E. Shulman</i> .....	129
Antibody-Mediated Lymphocytotoxicity in Rheumatoid Arthritis and Systemic Lupus Erythematosus <i>Efrain Diaz-Jouanen, Arthur D. Bankhurst, and Ralph C. Williams, Jr.</i> .....	133
Serum and Synovial Fluid Inhibitors of Antibody-Mediated Lymphocytotoxicity in Rheumatoid Arthritis and Systemic Lupus Erythematosus <i>Efrain Diaz-Jouanen, Arthur D. Bankhurst, Ronald P. Messner, and Ralph C. Williams, Jr.</i> .....	142
Esophageal Varices in Felty's Syndrome: A Case Report and Review of the Literature <i>Raymond W. Kloforn, James C. Steigerwald, David C. Mills, and Charley J. Smyth</i> .....	150
Effect of Aspirin on Liver Tests in Patients with RA or SLE and in Normal Volunteers <i>William E. Seaman and Paul H. Plotz</i> .....	155
Intraarticular Activation of the Complement System in Patients with Juvenile Rheumatoid Arthritis <i>Richard I. Rynes, Shaun Ruddy, Jocelyn Spragg, J. Sydney Stillman, and K. Frank Austen</i> .....	161
Acute Arthritis Caused by <i>Aeromonas Hydrophila</i> : Clinical and Therapeutic Aspects <i>Herman Chmel and Donald Armstrong</i> .....	169
Comprehensive Study of Humoral and Cellular Immune Abnormalities in 26 Patients with Systemic Amyloidosis <i>Morton A. Scheinberg and Edgar S. Cathcart</i> .....	173
Clinical Evaluation of Benzbromarone: A New Uricosuric Drug <i>Leif B. Sorensen and Dennis J. Levinson</i> .....	183
The Arthropathy of Relapsing Polychondritis <i>Michael O'Hanlan, Lawrence P. McAdam, Rodney Bluestone, and Carl M. Pearson</i> .....	191
Fibrinogen Catabolism in Systemic Lupus Erythematosus <i>John S. Sergent, Raymond L. Sherman, and Hamid Al-Mondhiry</i> .....	195
Metabolic Changes in Rabbit Articular Cartilage Due to Inflammation <i>Kalindi Deshmukh and Susan Hemrick</i> .....	199
Organization of Ground Substance Proteoglycans in Normal and Osteoarthritic Knee Cartilage <i>Kenneth D. Brandt and Marshall Palmoski</i> .....	209

Differentiation and Characterization of Autoantibodies and Their Antigens in Sjögren's Syndrome <i>Margaret A. Alsbaugh, Norman Talal, and Eng M. Tan</i> .....	216
Antigenic Profile of the Rat Chondrocyte <i>Zoriana M. Malseed and Susan Heyner</i> .....	223
Carpal Arthritis with Ankylosis in Late Onset Still's Disease <i>Thomas A. Medsger, Jr., and Wallace C. Christy</i> .....	232
Clinical Rounds: Deforming Arthritis of the Hands in Polymyositis <i>Thomas W. Bunch, J. Desmond O'Duffy, and Richard A. McLeod</i> .....	243
Discussion: <i>Michael D. Lockshin</i> .....	247
Clinical Rounds: Lupus Erythematosus in a Patient with Amyloidosis, Adrenal Insufficiency, and Subsequent Immunoblastic Sarcoma: Demonstration of the LE Phenomenon in the Lung <i>L. A. Schleissner, William W. Sheehan, and Richard C. Orselli</i> .....	249
Discussion: <i>Edgar S. Cathcart and Morton A. Scheinberg</i> .....	254
Review: A Pathogenetic Model for Erosive Synovitis: Lessons from Animal Arthritides <i>Norton M. Hadler</i> .....	256
Letters .....	267
Books Reviews .....	270
ARA Announcements .....	274

VOL. 19

MAY-JUNE

No. 3 (Supplement)

#### PART I: CLINICAL FEATURES

Calcium Pyrophosphate Dihydrate Crystal Deposition Disease—1975 <i>D. J. McCarty</i> .....	275
Arthroscopic Findings of the Knee in Patients with Pseudogout <i>Roy D. Altman</i> .....	286
Pseudogout: Clinical Observations and Chemical Analysis of Deposits <i>Taro Okazaki, Terunobu Saito, Toshio Mitomo, and Yasuo Siota</i> .....	293
Roentgenographic Aspects of Calcium Pyrophosphate Dihydrate Crystal Deposition Disease (Pseudogout) <i>Harry K. Genant</i> .....	307
Destructive Arthropathy in Chondrocalcinosis Articularis <i>C. J. Menkes, F. Simon, F. Delrieu, M. Forest, and F. Delbarre</i> .....	329
Clinical Studies of Acute Pseudogout Attacks: Comments on Prevalence, Predispositions, and Treatment <i>J. Desmond O'Duffy</i> .....	349
Diseases Associated with CPPD Deposition Disease <i>E. B. D. Hamilton</i> .....	353
Discussion. Moderator: D. J. McCarty .....	358
<b>PART II: GENETICS</b>	
Natural Course of Articular Chondrocalcinosis <i>D. Zitnan and S. Sitaj</i> .....	363

HL-A System in Articular Chondrocalcinosis <i>S. Nyulassy, J. Stefanovic, S. Sitaj, and D. Zitnan</i>	391
Articular Chondrocalcinosis in the Chiloe Islanders <i>Antonio J. Reginato</i>	395
Articular Chondrocalcinosis in a Dutch Pedigree <i>Jan K. Van der Korst and Jos Geerards</i>	405
Discussion. Moderator: D. S. Howell	410
PART III: PATHOLOGY AND CRYSTAL STUDIES	
Ultrastructure Findings in Chondrocalcinosis and Pseudogout <i>H. Ralph Schumacher</i>	413
Articular Chondrocytes in Culture. Matrix Production and Hormonal Effects <i>Leon Sokoloff</i>	426
Discussion: Moderator: Dr. Dusan Zitnan	430
PART IV: CRYSTAL STUDIES	
Protein Adsorption to Monosodium Urate, Calcium Pyrophosphate Dihydrate, and Silica Crystals <i>Franklin Kozin and Daniel J. McCarty</i>	433
The Structural Basis of Crystal-Induced Membranolysis <i>Neil S. Mandel</i>	439
Calcium Pyrophosphate Crystal Chemistry <i>W. E. Brown and T. M. Gregory</i>	446
Discussion: Moderator: James Lehr	462
PART V: METABOLISM	
Metabolism of Inorganic Pyrophosphate (PP <sub>i</sub> ) <i>R. G. G. Russell</i>	465
Inorganic Pyrophosphate and Proteoglycan Metabolism in Cultured Human Articular Chondrocytes and Fibroblasts <i>G. Lust, G. Nuki, and J. E. Seegmiller</i>	479
Pyrophosphate Release by Osteoarthritis Cartilage Incubates <i>David S. Howell, Ofelia Muniz, Julio C. Pita, and Jerry E. Enis</i>	488
Preliminary Observations on Phosphatases in Articular Cartilages <i>David S. Howell, Ofelia Muniz, Julio C. Pita, and Charalampos Arsenis</i>	495
Discussion: Moderator: R. G. G. Russell	499
Author Index	501
Subject Index	502

Altered Lymphocyte Reactivity in Rheumatoid Arthritis <i>H. Arthur Silverman, John S. Johnson, John H. Vaughan, and James C. McGlamory</i>	509
Hereditary C2 Deficiency: Association with Skin Lesions Resembling the Discoid Lesion of Systemic Lupus Erythematosus <i>Richard Stern, Shu Man Fu, Merilena Fotino, Vincent Agnello, and Henry G. Kunkel</i>	517
Induction of Peripheral Blood Lymphocyte Transformation by Autologous Synovial Fluid Lymphocytes and Synovial Fluid <i>James E. Crout, Frederic C. McDuffie, and Roy E. Ritts, Jr.</i>	523
Mixed Leukocyte Reaction in Rheumatoid Arthritis <i>Edward C. Keystone, Dafna D. Gladman, Murray B. Urowitz, David A. Clarke, Judy A. Falk, David Osoba, and Duncan A. Gordon</i>	532
Cellular Hypersensitivity in Rheumatoid Arthritis, Ankylosing Spondylitis, and Anterior Nongranulomatous Uveitis <i>E. J.-M. A. Thonar and M. B. E. Sweet</i>	539
Immunologic Observations on 9 Sets of Twins Either Concordant or Discordant for SLE <i>Sidney R. Block, Michael D. Lockshin, John B. Winfield, Marc E. Weksler, Masakatsu Imamura, Robert J. Winchester, Robert C. Mellors, and Charles L. Christian</i>	545
Predominance of T Cells in the Lymphocytic Infiltrates of Synovial Tissues in Rheumatoid Arthritis <i>Arthur D. Bankhurst, Gunnar Husby, and Ralph C. Williams, Jr.</i>	555
Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis <i>Alexander S. Townes, James M. Sowa, and Lawrence E. Shulman</i>	563
Identification of Antibodies to Nuclear Acidic Antigens by Counterimmunoelectrophoresis <i>N. Kurata and E. M. Tan</i>	574
Fine Structural Analysis of Rabbit Synovial Cells. II. Fine Structure and Rosette-Forming Cells of Explant and Monolayer Cultures <i>Phoebe R. Krey, Morton A. Scheinberg, and Alan S. Cohen</i>	581
Inhibition of Denaturation of Human Gamma Globulin by a Mixture of L-Histidine, L-Cystine, and Copper, and its Clinical Implication in Rheumatoid Arthritis <i>Donald A. Gerber</i>	593
Rheumatoid Factor (Antigammaglobulin) in Women: Effects of Oral Contraceptive Use on Its Prevalence <i>Ernest E. Sponzilli, Savitri Ramcharan, and John Wingerd</i>	602
Periarticular Uptake of <sup>99m</sup> Tc Diphosphonate in Psoriatics: Correlation with Cutaneous Activity <i>Thomas C. Namey and Leonard Rosenthal</i>	607
Antibodies to Native and Denatured Collagens in Sera of Patients with Rheumatoid Arthritis <i>Nicolaos A. Andriopoulos, Jiri Mestecky, Edward J. Miller, and Edwin L. Bradley</i>	613
Effect of Prophylactic Colchicine Therapy on Leukocyte Function in Patients with Familial Mediterranean Fever <i>Charles A. Dinarello, Michael J. Chusid, Anthony S. Fauci, John I. Gallin, David C. Dale, and Sheldon M. Wolff</i>	618
Obstructive Pulmonary Disease in Rheumatoid Arthritis <i>Ronald L. Collins, Robert A. Turner, A. Myron Johnson, Nancy O. Whitley, and Ross L. McLean</i>	623



Articular Manifestations of Hypertrophic Pulmonary Osteoarthropathy in Bronchogenic Carcinoma: A Clinical and Pathologic Study <i>H. Ralph Schumacher, Jr.</i> .....	629
Case Report: Genu Amoris <i>Robert S. Pinals</i> .....	637
Clinical Rounds: Hypertrophic Osteoarthropathy and Rheumatoid Arthritis: Simultaneous Occurrence in Association with Diffuse Interstitial Fibrosis <i>Stephen L. Schechter and Giles G. Bole</i> .....	639
Discussion: <i>H. Ralph Schumacher, Jr.</i> .....	643
Current Comment: A Uniform Database for Rheumatic Diseases <i>The Computer Committee of the American Rheumatism Association</i> .....	645
Letters .....	649
Book Reviews .....	651
ARA Announcements .....	654

VOL. 19

JULY-AUGUST

No. 4

Introduction to the Joseph J. Bunim Memorial Lecture <i>R. W. Lamont-Havers</i> .....	655
Joseph J. Bunim Memorial Lecture: HLA-B27 and the Inheritance of Susceptibility to Rheumatic Disease <i>D. A. Brewerton</i> .....	656
Allergy in Systemic Lupus Erythematosus <i>John A. Goldman, Grace Ann Klimek, and Rida Ali</i> .....	669
Combination Therapy with Naproxen and Aspirin in Rheumatoid Arthritis <i>Robert F. Willkens and Eugene J. Segre</i> .....	677
Hip Involvement in Ankylosing Spondylitis <i>Isaac L. Dwosh, Donald Resnick, and Michael A. Becker</i> .....	683
Prednisone and Azathioprine Compared to Prednisone Plus Low-Dose Azathioprine and Cyclophosphamide in the Treatment of Diffuse Lupus Nephritis <i>Ellen Ginzler, Herbert Diamond, Maria Guttadauria, and David Kaplan</i> .....	693
Lymphocytotoxic Antibodies in SLE Patients and Their Relatives <i>Inés Malavé, Rodolfo Papa, and Zulay Layrisse</i> .....	700
Clinical Studies of Antibodies Binding Polyriboadenylic Acid in Systemic Lupus Erythematosus <i>Rao J. Pillarisetty and Norman Talal</i> .....	705
Serum Antibody in Rheumatoid Arthritis Reactive with a Cell-Associated Antigen <i>Margaret A. Alspaugh and Eng M. Tan</i> .....	711

Lymphocyte Populations in Rheumatoid Arthritis <i>Arnold J. Rawson and T. C. Huang</i> .....	720
Antibody-Dependent Cell-Mediated Cytotoxicity in Rheumatoid Arthritis <i>Martin A. Isturiz, Maria M. de E. de Bracco, Ana M. Pizzi, and Jorge A. Manni</i> .....	725
Serum Immunoglobulins, Rheumatoid Factor, and Pneumoconiosis in Coal Miners with Rheumatoid Arthritis <i>Thomas G. Benedek, Zbigniew A. Zawadzki, and Thomas A. Medsger, Jr.</i> .....	731
The Role of Osmic Acid in the Treatment of Immune Synovitis <i>Victor M. Goldberg, Ralph Rashbaum, and Jocelyn Zika</i> .....	737
Mononuclear Cells in Human Synovial Fluid <i>Roger B. Traycoff, Eliseo Pascual, and H. Ralph Schumacher, Jr.</i> .....	743
P-Component of Amyloid <i>Merrill D. Benson, Martha Skinner, Tsuranobu Shirahama, and Alan S. Cohen</i> .....	749
Identity of a Peritoneal Fluid Immunoglobulin Light Chain and the Amyloid Fibril in Primary Amyloidosis <i>Paul J. Block, Martha Skinner, Merrill D. Benson, and Alan S. Cohen</i> .....	755
Pericardial Tamponade in Juvenile Rheumatoid Arthritis <i>J. Scharf, J. Levy, A. Benderly, and M. Nahir</i> .....	760
Cardiovascular Abnormalities in the Marfanoid Hypermobility Syndrome <i>Deborah J. Cotton and Kenneth D. Brandt</i> .....	763
Carrageenin-Induced Arthritis. I. The Effect of Intraarticular Carrageenin on the Chemical Composition of Articular Cartilage <i>Dennis A. Lowther and Gerald C. Gillard</i> .....	769
Chronic Arthritis Due to <i>Mycobacterium Intracellulare</i> <i>Don E. Cheatum, Victor Hudman, and Stephen R. Jones</i> .....	777
Arthritis Rounds: Ascites as the Major Manifestation of Systemic Lupus Erythematosus <i>Jacob Bitran, Dennis McShane, and Michael H. Ellman</i> .....	782
Discussion: <i>Eugene V. Ball</i> .....	786
Proceedings of the 40th Annual Scientific Session of the American Rheumatism Association: Abstracts of Papers Presented .....	787
Letters .....	832
Book Reviews .....	834
ARA Announcements .....	836

Significance of Persisting Serologic Abnormalities in SLE <i>Robert W. Lightfoot, Jr., and Graham R. V. Hughes</i>	837
Lymphocytotoxic Antibody Activity in Cryoprecipitates from Serum of Patients with SLE <i>Nathan J. Zvaifler and Harry G. Bluestein</i>	844
Characteristics of Patients with Serum Antibodies to Extractable Nuclear Antigens <i>James H. Leibfarth and Robert H. Persellin</i>	851
Comparison of the Complement-Fixing Activity of Antinuclear Antibodies in Lupus Nephritis, Mixed Connective Tissue Disease, and Scleroderma <i>Michael Dean Parker and Robert A. Turner</i>	857
Study of Thymic Factors. II. Failure of Thymosin to Alter the Natural History of NZB and NZB/NZW Mice <i>M. Eric Gershwin, Alfred D. Steinberg, Aftab Ahmed, and Craig Derkay</i>	862
Antibodies to dAT Detected by Membrane Filtration <i>Kenneth Lentz, John B. Winfield, and Peter Barland</i>	867
Lymphocyte Response to Mitogens in Progressive Systemic Sclerosis <i>Noel B. Salem and Jane H. Morse</i>	875
Association of Sjögren's Syndrome with HLA-B8 <i>Kenneth H. Fye, Paul I. Terasaki, Haralampos Moutsopoulos, Troy E. Daniels, Joseph P. Michalski, and Norman Talal</i>	883
Rheumatoid Factor in Acute Bacterial Endocarditis <i>John N. Sheagren, Carmelita U. Tuazon, Calvin Griffin, and Neville Padmore</i>	887
Connective Tissue Synthesis by Cultured Scleroderma Fibroblasts. I. In Vitro Collagen Synthesis by Normal and Scleroderma Dermal Fibroblasts <i>Jerome S. Perlish, Reza I. Bashey, Ralph E. Stephens, and Raul Fleischmajer</i>	891
Secondary Hypertrophic Osteoarthropathy: An Unusual Cause of Arthritis in Childhood <i>R. E. Petty, J. T. Cassidy, R. Heyn, A. G. Kenien, and R. L. Washburn</i>	902
Effects of Certain Antirheumatic Drugs on Normal Human Peripheral Blood Lymphocytes <i>Richard S. Panush</i>	907
Carrageenin-Induced Arthritis. II. Effect of Intraarticular Injection of Carrageenin on the Synthesis of Proteoglycan in Articular Cartilage <i>Gerald C. Gillard and Dennis A. Lowther</i>	918
Fibrous Myopathy: A Rheumatic Complication of Drug Abuse <i>Kent R. Johnson, Willa A. Hsueh, Sheldon M. Glusman, and Frank C. Arnett</i>	923
Intracellular Distribution of Radiogold: Localization to Large Granule Membranes <i>Neal S. Penneys, Sally McCreary, and Norman L. Gottlieb</i>	927
Effect of Fenoprofen Calcium on Acute Gouty Arthritis <i>Sunt Wanasukapunt, Yongsuk Lertratanakul, and Herbert M. Rubinstein</i>	933
Case Report: Gold Toxicity and Peritoneal Dialysis <i>Richard J. Combs, Mariellen M. Dentino, Linda Lehrman, and James J. Szwed</i>	936
Carpometacarpal Ratio: A New Quantitative Measure of Radiologic Progression of Wrist Involvement in Rheumatoid Arthritis <i>David E. Trentham and Alfonse T. Masi</i>	939
Association Between HLA and Cutaneous Necrotizing Venulitis <i>David Glass, Nicholas A. Soter, David Gibson, C. B. Carpenter, and Peter H. Schur</i>	945
Current Comment: Rheumatoid Vasculitis <i>David Glass, Nicholas A. Soter, and Peter H. Schur</i>	950



Clinical Rounds: Carcinomatous Polyarthritis: The Presenting Symptom of an Ovarian Tumor and Association with a Platelet Activating Factor	
<i>Robert M. Bennett, Mark H. Ginsberg, and Sharon Thomsen</i>	953
Discussion: <i>Thomas G. Benedek</i>	958
Editorial	960
Book Reviews	960
Letters	962
ARA Announcements	972

---

VOL. 19	NOVEMBER-DECEMBER	No. 6 (Supplement)
22ND RHEUMATISM REVIEW		973-1236

---

VOL. 19	NOVEMBER-DECEMBER	No. 6
Coagulation Abnormalities in Rheumatoid Disease		
<i>Doyt L. Conn, Frederic C. McDuffie, Francis J. Kazmier, Arnold L. Schroeter, and Nora C. J. Sun</i>		1237
The Lupus Anticoagulant		
<i>Michael Boxer, Leonard Ellman, and Angelina Carvalho</i>		1244
Clinical Significance of Immune Deposits in the Skin in SLE		
<i>David Wertheimer and Peter Barland</i>		1249
Frequency of Neoplasia in Systemic Lupus Erythematosus and Rheumatoid Arthritis		
<i>Robert B. Lewis, C. William Castor, Robert E. Knisley, and Giles G. Bole</i>		1256
IgG Antilymphocyte Antibodies in SLE Detected by <sup>125</sup> I Protein A		
<i>Ralph C. Williams, Jr., Arthur D. Bankhurst, and Jean D. Montaña</i>		1261
Lymphocyte Response to Virus Antigens in Systemic Lupus Erythematosus		
<i>Robert E. Wolf and Morris Ziff</i>		1271
Repeatability and Objectivity of Various Measurements in Rheumatoid Arthritis: A Comparative Study		
<i>D. R. Eberl, V. Fasching, V. Rahlfs, I. Schleyer, and R. Wolf</i>		1278
Carrageenin-Induced Arthritis. III. Proteolytic Enzymes Present in Rabbit Knee Joints After a Single Intraarticular Injection of Carrageenin		
<i>Dennis A. Lowther, Gerald C. Gillard, Elsmaree Baxter, Christopher J. Handley, and Kathryn A. Rich</i>		1287
Secretion and Localization of Cathepsin D in Synovial Tissues Removed from Rheumatoid and Traumatized Joints: An Immunohistochemical Study		
<i>A. R. Poole, R. M. Hembry, J. T. Dingle, I. Pinder, E. F. J. Ring, and J. Cosh</i>		1295
Aggregation of Cartilage Proteoglycans. II. Evidence for the Presence of a Hyaluronate-Binding Region on Proteoglycans from Osteoarthritic Cartilage		
<i>Kenneth D. Brandt, Marshall J. Palmoski, and Elaine Perricone</i>		1308

Hyaluronic Acid Produced by Human Synovial Fibroblasts: Effect of Polyinosinic-Polycytidylic Acid (Poly I:C) and Interferon <i>M. Yaron, I. Yaron, O. Smetana, E. Eylan, and M. Herzberg</i> .....	1315
Chrysotherapy: A Prospective Study <i>Norman O. Rothermich, Vol K. Philips, Waldemar Bergen, and Marvin H. Thomas</i> .....	1321
Serum Antibody Levels Against T Mycoplasmas in Two North American Indian Populations Predisposed to Spondylitis <i>Denys K. Ford and Elizabeth Henderson</i> .....	1328
Organic Brain Syndrome in Rheumatoid Arthritis Following Corticosteroid Withdrawal <i>Ved P. Gupta and George E. Ehrlich</i> .....	1333
Histochemical Investigation of Adjuvant-Induced Arthritis <i>Fred R. Nusbickel and Henry Troyer</i> .....	1339
Suppression of Autoimmunity in NZB Mice with Steroid-Sensitive X-Radiation-Sensitive Syngeneic Young Thymocytes <i>Robert O. Morton, Dawn G. Goodman, M. Eric Gershwin, Craig Derkay, Robert A. Squire, and Alfred D. Steinberg</i> .....	1347
Brief Communication: Physical Features of Patients with Ankylosing Spondylitis <i>Nourollah Parhami</i> .....	1351
Transfer of Spleen Cells from Young to Aging NZB $\times$ NZW F1 Hybrid Mice: Effect on Mortality, Antinuclear Antibody, and Renal Disease <i>Robert E. Wolf and Morris Ziff</i> .....	1353
Measuring Synovial Fluid Viscosity with a White Blood Cell Diluting Pipette: A Simple, Rapid, and Reproducible Method <i>Peter Hasselbacher</i> .....	1358
Hypothyroidism Presenting as a Polymyositis-Like Syndrome: Report of Two Cases <i>Marc C. Hochberg, Gerald M. Koppes, Corwin Q. Edwards, H. Verdain Barnes, and Frank C. Arnett, Jr.</i> .....	1363
Letters .....	1367
Book Reviews .....	1375
ARA Announcements .....	1376
Annual Indexes .....	1377

# AUTHOR INDEX

(Page numbers in italics refer to abstracts.)

## A

Abdin ZH, 803  
Agnello V, 517  
Agus B, 962  
Ahmed A, 862  
Akeson WH, 59  
Alarcón-Segovia D, 125, 796  
Alepa FP, 966  
Ali R, 699  
Al-Mondhiry H, 195  
Alspaugh MA, 216, 711, 787  
Altman RD, 1371  
Amiel D, 59  
Andiman WA, 824  
Andriopoulos NA, 613, 800  
Ansell B, 789  
Armstrong D, 169  
Arnett FC Jr, 129, 923, 1363  
Arroyave CM, 787, 829  
Asofsky R, 43  
Aucclair R, 788, 788, 831  
Auld WHR, 1368  
Austen KF, 161

## B

Baldassare A, 788, 788, 831  
Ball EV, 786  
Bankhurst AD, 133, 142, 555, 1261  
Barland P, 867, 1249  
Barnes HV, 1363  
Barone R, 964  
Bashey RI, 891  
Bass JC, 788  
Bastian D, 818  
Baum J, 807  
Baxter E, 1287  
Becker MA, 683  
Bell RAF, 1373  
Benderly A, 760  
Benedek TG, 731, 835, 958  
Bennett JC, 653, 960, 1375  
Bennett PH, 791  
Bennett RM, 93, 789, 791, 810, 953, 963  
Bensasson ML, 833  
Benson MD, 749, 789, 822, 822  
Benya P, 793  
Bergen W, 1321  
Berman L, 813  
Bernstein BH, 789, 822  
Berry DC, 971  
Bias WB, 129  
Bitran J, 782

Block SR, 545  
Bluestein HG, 805, 831, 844  
Bluestone R, 191, 828, 833  
Bobrove AM, 790  
Bole GG, 639, 790, 1256  
Boxer M, 1244  
Bradley EL, 613  
Brandt KD, 209, 763, 1308, 1367  
Brauer D, 792  
Braun WE, 804  
Bresnahan B, 791  
Brewer E, 807  
Brewerton DA, 656  
Brinkman JP, 809  
Bromige M, 971  
Brown DH, 1368  
Brown MM, 269  
Brown TMcP, 650  
Broyles JT, 788  
Buckelew J, 794  
Buckingham RB, 816, 817  
Bunch TW, 123, 243, 248  
Bywaters EGL, 789

## C

Calabro JJ, 273  
Caldwell JR, 806  
Calin A, 791, 791  
Callera ML, 792  
Canoso JJ, 820  
Caperton EM, 792  
Carpenter CB, 945  
Carvalho A, 1244  
Cassidy JT, 808, 902  
Castor CW, 1256  
Cathcart ES, 173, 254, 831  
Cavallo T, 817  
Chandler RW, 814  
Chase G, 49  
Chase PH, 964  
Cheatum DE, 777  
Cheung H, 793  
Chmel H, 169  
Christian CL, 545, 809  
Christy WC, 232  
Chused TM, 797  
Chusid MJ, 618  
Clark HW, 649  
Clarke DA, 532  
Cohen AS, 581, 755, 789, 820, 822, 822  
Cohen J, 651  
Cohn H, 811  
Collier DH, 811  
Collins RL, 623, 827  
Combs RJ, 936  
Condemi JJ, 792

Conn DL, 15, 111, 824, 1237  
Convery FR, 59  
Cordon R, 801  
Cosh J, 1295  
Cotton DJ, 763  
Cottrel W, 793  
Crout JE, 523  
Crugnola A, 793  
Cunningham NE, 1368  
Cyprus GS, 79

## D

Dale DC, 618  
Dale IM, 1373  
Daniels TE, 883  
Davis P, 793  
Dayer J-M, 794  
de Bracco MMdeE, 725  
DeChatelet L, 827  
Decker JL, 819  
Deesomchock U, 824  
Dehner LP, 792  
DeHoratius RJ, 794  
Dentino MM, 936  
Derkay C, 862, 1347  
de Seze S, 833  
Deshmukh K, 199  
DeWind LT, 797  
Diamond HS, 693, 811  
Diaz-Jouanan E, 133, 142  
DiBartolomeo AG, 794  
Dinarello CA, 618  
Dingle JT, 1295  
Dorfmann H, 833  
Dornfeld L, 833  
Dubois EL, 83  
Dubois RW, 83  
Durward WF, 123  
Dwosh IL, 683, 795, 795

## E

Eberl DR, 1278  
Edwards CQ, 1363  
Ehrlich GE, 806, 1333  
Eisenbeis CH, 823  
Ellman L, 1244  
Ellman MH, 782  
Emery H, 795  
Emori W, 796  
Esdaile JM, 795  
Esterly J, 49  
Evans J, 802  
Eylan E, 1315

## F

Falk JA, 532, 795

Fasching V, 1278  
Fauci AS, 618  
Faulkner CS II, 801  
Feigenbaum SL, 814  
Feigl P, 820  
Ferguson RH, 111  
Fernandez-Diez J, 812  
Fernandez-Herlihy L, 832  
Fink CW, 807  
Fishbein E, 796  
Fleischmajer R, 891  
Foad BSI, 122  
Ford DK, 1328  
Forrester D, 789  
Fotino M, 517  
Fowler RS Jr, 795  
Franck WA, 269  
Freyberg RH, 271  
Friou GJ, 797  
Fritzsch H, 968  
Fu SM, 517  
Furst DE, 267, 796  
Fye KH, 811, 883

## G

Galindo LF, 812  
Gallacher A, 823  
Gallin JI, 618  
Gehle WD, 801  
Gelfand MC, 43  
Gerber DA, 593  
Gershwin ME, 797, 862, 1347  
Giangiacoma J, 831  
Gibson D, 798, 945  
Gillard GC, 769, 918, 1287  
Gilliam JN, 797, 815  
Ginsburg JH, 797, 953  
Ginzler E, 693  
Giuliano VJ, 791  
Gladman DD, 532, 826  
Glass D, 798, 817, 945, 950  
Glauert AM, 801  
Glinski W, 797  
Glusman SM, 923  
Goldberg LS, 828  
Goldberg MA, 129  
Goldberg VM, 737, 798, 798, 813  
Goldenberg DL, 820  
Goldman AL, 791  
Goldman JA, 650, 669  
Good AE, 1372  
Goodman DG, 1347  
Gordon DA, 532  
Gottlieb NL, 927  
Grady RF, 962  
Gray RG, 1371

Green A, 806  
Greenwald RA, 799, 799  
Grelier JM, 800  
Griffin C, 887  
Grishman E, 824  
Gupta N, 267  
Gupta VP, 1333  
Guttadauria M, 693

## H

Hadler NM, 256  
Hague JM, 1372  
Hahn B, 800, 810, 826, 966  
Hahn T, 800  
Hamanishi C, 800  
Handley CJ, 1287  
Hanson V, 789, 807, 822, 825  
Hardin JG, 272, 800, 960  
Hargrave R, 816  
Harmon C, 801  
Harrington JT Jr, 801  
Harris ED Jr, 68, 801, 809, 812  
Harris ER, 814  
Harth M, 802  
Hasselbacher P, 802, 1358  
Hathaway DE, 792  
Hausknecht M, 810  
Held C, 801  
Hembry RM, 1295  
Hemrick S, 199  
Henderson E, 1328  
Herd JK, 1370  
Herzberg M, 1315  
Hess EV, 122, 645  
Hettig RA, 79  
Heyn R, 902  
Heyner S, 223  
Hochberg MC, 1363  
Horwitz DA, 802  
Hough A, 835  
Howard A, 789  
Howell DS, 961  
Hsu K, 38  
Hsueh WA, 923  
Huang TC, 720  
Hudman V, 777  
Hughes GRV, 837  
Hunder GG, 126, 803, 815  
Hunter T, 795  
Husby G, 555, 803, 821  
Hutchison RM, 793  
Hymes AJ, 813

## I

Imamura M, 545  
Ishikawa H, 1  
Isturiz MA, 725  
Ito T, 800

## J

Jasin HE, 791, 803  
Jayson MIV, 971  
Jimenez FJ, 812  
Jimenez SA, 804  
Johnson AM, 623  
Johnson JS, 509  
Johnson KR, 923  
Jones SR, 777  
Jupiter J, 791  
Juul-Nielsen K, 802

## K

Kagen LJ, 804  
Kahn M-F, 833  
Kamel H, 1368  
Kaplan D, 693  
Kaplan SB, 814  
Kar NC, 267  
Katholi RE, 651  
Katz AL, 966  
Kaye JJ, 127  
Kazmier FJ, 1237  
Kenien AG, 902  
Kerby GP, 969  
Kettlekamp DB, 1367  
Keystone EC, 532  
Khan MA, 798, 804  
King KK, 789, 822  
Klimek GA, 669  
Kline S, 1371  
Klippel JH, 805  
Klofakorn RW, 150  
Knisley RE, 1256  
Kolarz G, 968  
Kondo H, 805  
Koppes GM, 1363  
Kornreich HK, 789, 822  
Kozin F, 805  
Krane SM, 794  
Krey PR, 581  
Kunkel HG, 517  
Kurata N, 574  
Kushner I, 798, 804

## L

Laham MN, 806  
Lamont-Havers RW, 655  
Layrisse Z, 700  
Lazarus D, 799  
Lehr JR, 93  
Lehrman L, 936  
Leibfarth JH, 851  
Lentz K, 867  
Leon SA, 806  
LeRoy EC, 809  
Lertratanakul Y, 933  
Levine S, 21, 796  
Levinson DJ, 183  
Levinson JE, 807  
Levitin PM, 651

Levy J, 760, 807  
Lewis RB, 1256  
Lightfoot RW Jr, 837  
Lillard S, 801  
Lin T-Y, 829  
Lindamood M, 807  
Lippiello L, 127  
Lipsky PE, 808  
Litwin A, 122  
Lloyd-Jones K, 971  
Locker JD, 810, 963  
Lockshin MD, 247, 545  
Loehnen PE, 824  
Lowther DA, 769, 918, 1287  
Luthra HS, 111

## M

McAdam LP, 191  
McCarty DJ, 56, 93, 805  
McChesney LF, 825  
McCombs C, 811  
McCravey JW, 826  
McCreary S, 927  
McDuffie FC, 15, 270, 523, 803, 1237  
McGirr D, 802  
McGlamory JC, 509  
McGuire MB, 818  
Machleder HI, 814  
McKenna CH, 824  
McLean RL, 623  
McLeod RA, 243, 248  
McShane D, 782  
Maddison PJ, 808  
Magilavy DB, 808  
Mainardi C, 799, 809  
Malavé I, 700  
Malawista SE, 824  
Malcom LL, 59  
Malseed ZM, 223  
Mandell B, 823  
Mankin HJ, 652  
Manni JA, 725  
Maricq HR, 809  
Markenson JA, 809  
Mashburn H, 827  
Masi AT, 814, 826, 939  
Maurer K, 821  
Medof ME, 810, 964  
Medsker TA Jr, 232, 731, 823  
Mehta J, 810  
Meisel AD, 811  
Mellors JW, 811  
Mellors RC, 545, 811  
Messner RP, 142, 794, 821  
Mestecky J, 613  
Metzger A, 796  
Michalski JP, 811, 883  
Miller B, 807  
Miller EJ, 613  
Miller J, 821  
Miller JJ III, 115

Miller P, 790  
Mills DM, 150, 807  
Milne R, 826  
Mintz G, 812  
Mitre BK, 823  
Mongan ES, 797  
Montaño JD, 1261  
Montoya HE, 791  
Morgan GJ Jr, 812  
Morris AD, 49  
Morse JH, 875  
Morton RO, 1347  
Moskowitz RW, 813  
Moutsopoulos H, 883  
Moy WW, 799, 799  
Mullinax F, 813  
Mullinax GL, 813  
Myers AR, 813, 828

## N

Nagai J, 800  
Nahir M, 122, 760, 1373  
Namey TC, 607  
Narins RG, 828  
Nasrallah NS, 814  
Natelson EA, 79  
Newton CD, 970  
Nimni M, 793  
Nirenberg L, 1373  
Niwayama G, 818  
Novak A, 119  
Nusbickel FR, 1339  
Nyman KE, 814

## O

O'Brien WM, 791  
Ochs H, 820  
O'Duffy JD, 243, 248, 815  
Ogryzlo MA, 795, 795  
O'Hanlan M, 191  
Orselli RC, 249  
Osoba D, 532  
Ottaway JM, 1368

## P

Padmore N, 887  
Palmoski M, 209, 1308  
Pandya MR, 962  
Panush RS, 806, 907  
Papa R, 700  
Papioian R, 819  
Parhami N, 1351  
Parker DM, 827, 857, 969  
Pascual E, 743  
Paulus HE, 21, 267, 796, 814  
Pearson CM, 191  
Pennebaker J, 815  
Penneys NS, 927  
Perez-Busquier M, 833  
Perlish JS, 891

Perper RJ, 829  
 Perricone E, 1308  
 Persellin RH, 815, 825, 851  
 Petty RE, 808, 902  
 Phillips VK, 1321  
 Phillips PE, 809, 816  
 Pillarisetty RJ, 705, 819  
 Pinals RS, 637  
 Pinder I, 1295  
 Pizzi AM, 725  
 Plotz PH, 155  
 Poland M, 806  
 Poole AR, 1295  
 Poss R, 834  
 Powell AE, 798, 798  
 Prince RK, 816, 817  
 Pritzker KPH, 817

## Q

Quismorio FP, 797, 825

## R

Rabin BS, 794, 805, 823  
 Radin E, 793  
 Rahlfs V, 1278  
 Ramcharan S, 602  
 Rashbaum R, 737  
 Raum D, 798, 817  
 Rawson AJ, 720  
 Reginato AJ, 821  
 Reichlin M, 808  
 Resnick D, 683, 818  
 Reyes PA, 818  
 Rich KA, 1287  
 Richards AJ, 650  
 Ring EFJ, 1295  
 Ritts RE Jr, 523  
 Robinson DR, 818  
 Rodnan GP, 794, 805, 816, 817  
 Rooney PJ, 819  
 Rosenberg D, 823  
 Rosenthal L, 607  
 Roth GJ, 119  
 Rothermich NO, 1321  
 Roubinian JR, 819  
 Rubinow A, 820  
 Rubinstein HM, 833  
 Ruddy, S, 161  
 Russell RGG, 794  
 Rynes RI, 161

## S

Sakofsky Y, 791  
 Salem NB, 875

Sarkissian ES, 267  
 Schaller JG, 795, 807, 820, 820  
 Scharf J, 122, 760, 1373  
 Schechter SL, 639, 1372  
 Scheiderer LM, 790  
 Scheinberg MA, 173, 254, 581, 831  
 Scherak O, 968  
 Schiller A, 793  
 Schleissner LA, 249  
 Schleyer I, 1278  
 Schmid FR, 791  
 Schroeter AL, 15, 1237  
 Schumacker HR Jr, 629, 643, 743, 802, 813, 821, 827  
 Schunke P, 798  
 Schur PH, 43, 798, 817, 945, 950, 964  
 Schwartz HA, 1369  
 Seaman WE, 155  
 Searles RP, 821  
 Segre EJ, 677  
 Sergeant JS, 195  
 Shapiro B, 806  
 Shapiro R, 818  
 Sharp GC, 49, 801, 830  
 Sheagren JH, 887  
 Sheehan WW, 249  
 Sherman RL, 195  
 Shirahama T, 749, 822  
 Shulman LE, 29, 129, 563  
 Silverman HA, 509  
 Sinclair N, 802  
 Singsen BH, 822  
 Skinner M, 749, 822, 822  
 Skosey JL, 789  
 Sledge CB, 828  
 Smetana O, 1315  
 Smith CA, 823  
 Smith KO, 801  
 Smith WE, 1368  
 Smyth CJ, 150  
 Smythe HA, 795, 795  
 Snyderman DR, 824  
 Sorensen LB, 183  
 Soter NA, 817, 945, 950  
 Sowa JM, 563  
 Spiera H, 824  
 Spilberg I, 823, 966  
 Sponzilli EE, 267, 602  
 Spragg J, 161  
 Squire RA, 1347  
 Srinivasan R, 796  
 Starz TW, 823  
 Steere AC, 824  
 Steigerwald JC, 150, 807

Stein HB, 795, 795  
 Steinberg AD, 43, 797, 819, 862, 1347  
 Steinman CR, 38, 824  
 Stephens RE, 891  
 Stern R, 517  
 Stevens MB, 1375  
 Stewart A, 1367  
 Stewart E, 816  
 Stiller CR, 802  
 Stillman JS, 161, 798, 817  
 Stobie DG, 825  
 Stobo JD, 824  
 Sugarman M, 825  
 Sukhupunyaraksa S, 791, 810, 963  
 Sullivan DB, 808  
 Sun NCJ, 1237  
 Sweet MBE, 539  
 Szwed JJ, 936

## T

Takeuchi A, 825  
 Talal N, 216, 705, 811, 819, 883, 964  
 Tan EM, 216, 574, 711, 787, 787, 818, 822, 829  
 Tan RF, 826  
 Tanphaichitr K, 826, 966  
 Terasaki PI, 791, 811, 883  
 Thoi LL, 815  
 Thomas ED, 820  
 Thomas MH, 270, 1321  
 Thomsen S, 953  
 Thonar EJ-MA, 539  
 Tolchin SF, 823  
 Townes AS, 563  
 Traycoff RG, 743  
 Trentham DE, 826, 939  
 Troyer H, 1339  
 Tsai C, 788, 831  
 Tse R, 821  
 Tuazon CU, 887  
 Tudor RB, 651  
 Turner RA, 623, 827, 857

## U

Urowitz MB, 532, 795, 795  
 Utsinger PD, 88, 818, 827

## V

Van de Rijn I, 803  
 Van Linder S, 828  
 Vater CA, 809  
 Vaughan JH, 509, 829

Volz RG, 828

## W

Wahner H, 815  
 Walike JW, 119  
 Wallace SL, 964  
 Wanasukapunt S, 933  
 Washburn RL, 902  
 Wedgwood RJ, 820, 820  
 Weiner JM, 83  
 Weisbart RH, 828  
 Weisberg JW, 828  
 Weisman M, 103  
 Weiss T, 788, 788  
 Weissel M, 968  
 Weissman DB, 115  
 Weksler ME, 545  
 Werb Z, 809  
 Wertheimer D, 1249  
 Whitley NO, 623  
 Wild JH, 98  
 Williams HR, 829  
 Williams RC Jr, 133, 142, 555, 803, 1261  
 Willkens RF, 119, 677, 791  
 Wilson MR, 829  
 Wilson SE, 830  
 Winchester RJ, 545  
 Winfield JB, 545, 867  
 Wingerd J, 602  
 Wolf R, 1278  
 Wolf RE, 1271, 1353  
 Wolfe JF, 801, 830  
 Wolff SM, 618  
 Woo SL-Y, 59

## Y

Yamasaki K, 830  
 Yaron I, 1315  
 Yaron M, 1315  
 Yonkosky D, 831  
 Yount WJ, 827

## Z

Zabriskie J, 803  
 Zawadzki ZA, 731  
 Ziff M, I, 791, 808, 815, 830, 1271, 1353  
 Zika J, 737  
 Zuberi R, 802  
 Zuckner J, 788, 788, 831  
 Zurier RB, 73  
 Zvaifler NJ, 98, 103, 805, 831, 844



# SUBJECT INDEX

## ARTHRITIS AND RHEUMATISM, Vol. 19, 1976

Page numbers in italics refer to abstracts. The *Conference on Pseudogout and Pyrophosphate Metabolism* (pp 275-508) and the *22nd Rheumatism Review* (pp 973-1237) are indexed separately.

### A

- Acetaminophen, 907
  - lymphocytes and, 911
- Acetylsalicylic acid, 907
  - lymphocytes and, 910
- Acetyl transferase activity, in SLE, 796
- Acute anterior uveitis, HLA antigens in, 660
- Acute lymphocyte choriomeningitis, 657
- Acute polyarticular gout, Ibuprofen in, 269
- Acute pseudogout, crystal shedding and, 93-97
- ADCC, *see* Antibody-dependent cell-mediated cytotoxicity
- Adenine/thymidine nucleotides, in <sup>14</sup>C-dAT, 867
- Adenosine triphosphatase, in adjuvant arthritis, 1340, 1342-1344
- Adjuvant arthritis, 257-259
  - cartilage matrix histochemistry in, 1341-1343
  - clinical description of, 257
  - erosive synovitis and, 256
  - Freund's adjuvant in, 259
  - gross and histologic alterations in, 1340
  - histochemical investigation in, 1339-1345
  - histopathology of, 258
  - immunobiology of, 258-259
  - wax D in, 259
- Adrenal insufficiency, in SLE, 249-252
- Aeromonas hydrophilia*, in acute arthritis, 169-171
- Affinity chromatography, amyloid P-component separation with, 749-753
- Agammaglobulinemia, rheumatoid arthritis and, 555
- Allergic angiitis, 949
- Allergic disorders, defined, 669-670
- Allergy questionnaire, 670-671
- Allied Health Professions, 33
- American Cancer Society, 36
- American Heart Association, 36
- American Indian populations, ankylosing spondylitis in, 1328-1332
- American Rheumatism Association, 29-30, 97, 655
  - Computer Committee of, 645-647
  - proceedings of, 787
- American Rheumatism Association Directory*, 56
- American Rheumatism Association Medical Information System, 646
- Amyloid
  - Bence-Jones protein in, 173, 180
  - deposition of, 173
- Amyloid fibrils
  - isolation and purification of, 756
  - in primary amyloidosis, 755-758
- Amyloidosis
  - B-cell activation and macrophage dysfunction in, 831
  - B-cell "escape" in, 254
  - Bence-Jones proteins and, 173
  - bovine thymic hormone in, 180
  - concanavallin A and, 179
  - defined, 173-174
  - DNA synthesis in, 179-180
  - hereditary, 174
  - leukemia-lymphoma and, 174-177
  - lymphocyte transformation studies in, 176-177
  - multiple myeloma and, 174-177
  - primary, 174, 755-758
  - serum and urine immunoglobulin abnormalities in, 175
  - SLE and, 249-252
  - thymosin in, 180
- Amyloid P-component, 749-753
  - sequence analysis in, 822
- Amyloid P-component protein, 749-753
- Amyloid protein SAA levels, in JRA, 789
- ANA, *see* Antibodies to nuclear antigens
- Ankylosing hyperostosis, of spine, 818
- Ankylosing spondylitis
  - in American Indians, 1328-1332
  - axial migration in, 686-687
  - case reports in, 111-112
  - cellular hypersensitivity in, 539-543
  - in childhood, 662
  - coexistence with RA, 111-114
  - definition of, 660
  - hip involvement in, 683-692
  - hip surgery in, 691-692
  - HLA antigens and, 659-660
  - HLA-B27 antigen in, 804-805, 883
  - impairment of lymphocyte responsiveness in, 798
  - life expectancy in, 689
  - osteoarthritic controls in, 689
  - penicillamine in, 122
  - physical features of patients with, 1351-1352
  - postoperative heterotopic ossification in, 690
  - superior migration in, 686-688
- Ankylosis
  - carpal arthritis and, 232-241
  - in JRA, 240
- Anterior nongranulomatous uveitis, 539-543
- Antibodies
  - identification of by counterimmunoelectrophoresis, 574-579
  - polyriboadenylic acid bonding of in SLE, 705-709
  - to extractable nuclear antigens, 851-856
  - to native and denatured collagens in RA, 613-616
- Antibodies to IgA, in rheumatic and pulmonary disease, 792
- Antibodies to nuclear antigens
  - in mixed connective tissue disease, 574-575
  - in Sjögren's syndrome, 574
  - in SLE, 574, 786
- Antibody-dependent cell-mediated cytotoxicity in RA, 725-729
- Antibody-mediated lymphocytotoxicity, *see* Lymphocyte-dependent antibody toxicity
- Antibody response, to rat chondrocyte injection, 225
- Anticoagulant therapy, hemoarthrosis and, 99
- Anticollagen autoantibodies, in RA, 539
- Anticomplementary activity, in SLE, 74
- Anti-DNA, nephritis and, 49
- Anti-EI serum, 39
- Anti-ENA, *see* Extractable nuclear antigens
- Anti-gammaglobulins
  - in RA, 613
  - in women, 602-606
- Antigen-antibody complexes, in RA, 613
- Antigen pronestyl-human serum albumin, in SLE, 794
- Antigens

- nuclear, *see* Nuclear antigens
  - in twin SLE studies, 545-552
  - Antilymphocyte antibodies
    - in SLE, 821
    - in SLE twin studies, 549
  - Anti-nDNA antibodies, in SLE, 815, 867
  - Antinuclear antibodies
    - complement-fixing, 857-860
    - in Felty's syndrome, 105
    - nonhistone nuclear protein and, 818
    - in NZB mice, 1354-1355
    - in polymyositis, 830
    - in RA, 712
    - in SLE, 702
  - Antirheumatic drugs, human peripheral blood lymphocytes and, 907-916
  - Anti-RNA antibody, in SLE, 1265
  - ANU, *see* Anterior nongranulomatous uveitis
  - Aortitis, 662
  - ARA, *see* American Rheumatism Association
  - Arachnodactyly, in Marfanoid hypermobility syndrome, 764
  - ARA Index, 1278, 1281, 1283
  - ARA Joint Count, 1278
  - Arboviruses, arthritis and, 1317
  - Arteritis
    - digital, 19
    - temporal, 812
  - Arthritides, erosive inflammatory, 256
  - Arthritis
    - adjuvant, *see* Adjuvant arthritis
    - Aeromonas hydrophila* as cause of, 169-171
    - azaribine in, 21
    - avian reovirus and, 830
    - B27 positive patients with, 820
    - calcium pyrophosphate dihydrate induced, 823
    - carpal, 232-241
    - carrageenin-induced, 769-775, 918-921, 1287-1293
    - childhood, *see* Childhood arthritis
    - crystal-induced, 821
    - degenerative, *see* Degenerative arthritis
    - detection of organisms in, 38-42
    - Erysipelothrix*, *see* *Erysipelothrix* arthritis
    - gonococcal, 826-827
    - gouty, *see* Gouty arthritis
    - of hands, in polymyositis, 243-248
    - of knee, 637-638
    - psoriatic, 651, 661, 663
    - reactive, 664-665
    - in relapsing polychondritis, 192
    - rheumatoid, *see* Rheumatoid arthritis
    - rheumatoid factor negative, 814
    - septic, *see* Septic arthritis
    - streptococcal cell wall induced, 260-264
    - of subacute bacterial endocarditis, 813-814
  - Arthritis Coordinating Committee, 29
  - Arthritis Data Bank, 29
  - Arthritis Foundation, 29-31, 56, 655
  - Arthritis Plan, 29
  - Arthritis Programs, directors of, 33
  - Arthrocentesis, of knee, 234
  - Arthropathy, trapezioscaphoid, 833
  - Articular cartilage
    - ATPase activity in, 1337
    - collagen biosynthesis in, 793
    - erosion of, 769-772
    - intraarticular carrageenin and, 769-775
    - irreversible joint destruction and, 68
    - metabolic changes due to inflammation in, 199-207
    - metabolism of, 828
    - proteoglycan depletion from, 68
    - proteoglycan synthesis in, 918-921
  - Articular tissues, CPPD deposition in, 93-97
  - AS, *see* Ankylosing spondylitis
  - Ascites, in SLE, 782-785
  - L-Asparaginase, in lupus nephritis, 810
  - Aspirin
    - benzbromarone and, 188-189
    - BUN level and, 157-160
    - glomerular filtration rate and, 159
    - liver function and, 155-160
    - Naproxen and, in RA combination therapy, 677-681
    - in RA, 155-160
    - in SLE, 155-160
    - tolmetin and, in JRA, 807
  - Atherosclerosis, hemarthrosis and, 98
  - ATPase, *see* Adenosine triphosphatase
  - Autoantibodies
    - in Sjögren's syndrome, 216-222
    - in SLE, 88-90
  - Autoimmune nephritis, in NZB/W mice, 43
  - Autoimmunity, suppression of in NZB mice, 1345-1347
  - Autologous system, mixed leukocyte reaction in, 535
  - Azaribine
    - categories of clinical response to, 24
    - clinical response to by category of improvement, 23
    - clinically active joints and, 23
    - in dermatitis, 21, 27
    - dosage for, 22, 27-28
    - efficacy measurement for, 23
    - gastrointestinal complaints from, 27
    - liver and, 27
    - mechanism of, 27
    - number of pills needed for, 28
    - orotidylate decarboxylase inhibition by, 21
    - in pregnancy, 28
    - in psoriatic arthritis, 21-28
    - response spectrum for, 24-25
    - side effects of, 23-24, 27-28
    - sperm count and, 28
    - toxicity of, 25-27
  - Azathioprine
    - autoimmune nephritis and, 43
    - cyclophosphamide and, 54, 693-698
    - in early RA, 795
    - in lupus glomerulonephritis, 819
    - in NZB/W nephritis, 46, 48
    - prednisone and cyclophosphamide in, 693-698
    - in psoriatic arthritis, 28
    - vaccinia and, 270
  - 6-Azauridine 5'-monophosphate, 21
  - see also* Azaribine
  - 6-Azauridine triacetate, 21, 27
- B**
- Bacitracin, articular cartilage and, 828
  - Bacterial endocarditis
    - rheumatoid factor and, 887-890
    - Staphylococcus aureus* and, 887
  - BAL, *see* British Anti-Lewisite
  - B-cell dyscrasias, 173
  - B cells, *see* B lymphocytes
  - Behçet's syndrome, 32
  - HLA antigens and, 659
  - Bella Coola Indians, ankylosing spondylitis in, 1329
  - Bence-Jones protein, 756
    - amyloidosis and, 173, 180
    - anti- $\kappa$  antisera and, 756
    - degrading of, 758
  - Benign essential hypertension, neoplasia and, 1257
  - Benign monoclonal gammopathy, 175
  - Benzbromarone
    - aspirin and, 188
    - clinical evaluation of, 183-189
    - defined, 183

dosage of, 175-187  
 hyperuricosuria and, 184  
 purine biosynthesis of, 189  
 Biofeedback, in Raynaud's phenomenon, 795  
 Blast cells, in rheumatoid synovitis transitional areas, 5-8  
 Blastogenic responses, calculation of, 510  
 Blood L lymphocytes, in SLE, RA, and scleroderma, 802-803  
 Blood urea nitrogen level, aspirin and, 157-160  
 B lymphocytes  
   in amyloidosis, 175-176  
   in familial Mediterranean fever, 618  
   macrophages and, 8-10  
   in rheumatoid synovitis, 8-10  
 BMG, *see* Benign monoclonal gammopathy  
 Bovine cartilage, proteoglycan fractions for, 1310  
 Bovine knee cartilage, normal vs osteoarthritic, 211  
 Bovine serum albumin, thermal denaturation of, 595  
 Brain scan, in SLE, 826  
 British Anti-Lewisite, in gold overdose, 123-124  
 5-Bromodeoxyuridine, in lymphocyte measurement, 720-723  
 Bronchogenic carcinoma, 629-635  
 BUDR, *see* 5-Bromodeoxyuridine  
 BUN, *see* Blood urea nitrogen  
 Bunim Memorial Lecture, 655-665  
 Butazolidin, in ankylosing spondylitis, 111

## C

C2 complement dependency, 517-522, 798  
   skin lesions in, 521  
 C3 complement, activation of by sera and synovial fluids, 803  
 Calcium pyrophosphate dihydrate crystals, 93-97, 967  
   arthritis and, 823  
   corticosteroids and, 1369-1370  
   removal of, 96  
   solubility of, 94, 96  
*Candida*, in SLE, 89-90  
 Canine hemoarthrosis, 59-66  
   *see also* Hemoarthrosis  
 Caplan's syndrome, 32  
 Carcinoma, bronchogenic, *see* Bronchogenic carcinoma  
 Carcinomatous polyarthritis, 953-957  
   radiogallium uptake in, 955  
 Carpal arthritis, 232-241  
 Carpal tunnel, *Mycobacterium intracellulare* infection and, 777-780  
 Carpo/metacarpal ratio, in rheumatoid arthritis, 939-944  
 Carrageenin  
   inflammatory response to, 775  
   intraarticular injection of, 771  
   lysosomal enzyme stimulation of, 1291-1292  
   multiple injection of, 773  
   phagocytic cell uptake of, 775  
 Carrageenin-induced arthritis, 769-775, 918-921, 1287-1293  
 Cartilage  
   articular, *see* Articular cartilage  
   biosynthesis of matrix components of, 202  
   cathepsin D and, 1296  
   deformation of in hemarthrosis, 63  
   hexosamine in, 62  
   mechanical properties of, 209  
   proteoglycan contents of, 771  
   transplantation of, 223  
 Cartilage antigens, humoral response to, 223  
 Cartilage destruction, collagen loss and, 68-69  
 Cartilage proteoglycans  
   aggregation of, 1308-1314  
   degradation of by superoxide radical, 799  
   enhancement of collagenase activity by, 799  
 Cathepsin B1, in cartilage degradation, 1293  
 Cathepsin D  
   autoradiographic studies and, 1303-1304  
   detection of in extracellular locations, 1298-1303  
   lysosomal enzyme activity and, 1291-1292  
   operating theater cultures and, 1303  
   in osteoarthritic cartilage, 205  
   preparation of, 1288  
   rat chondrocyte antigens and, 230  
   secretion and localization of in synovial tissues, 1295-1305  
   synovial, 738, 1295-1305  
 Cell-associated antigen, in RA, 711-718  
 Cell-mediated immunity, decrease of, 1274-1275  
 Cellular hypersensitivity, in RA and in ankylosing spondylitis, 539-543  
 Cellular immune abnormalities, in amyloidosis, 173-180  
 CEMPAF, *see* Committee for the Evaluation of the Medical Programs of the Arthritis Foundation  
 Cerebral radionuclide angiogram, in SLE, 826  
 CFANA, *see* Complement fixing antinuclear antibody  
 CH50 (total hemolytic component), in JRA, 161-166  
 Chapter Medical Program Subcommittee, 33  
 Charnley total hip prosthesis, 691  
 Chemotaxis, polymorphonuclear leukocyte, 825-826  
 Childhood arthritis, 820, 824  
   B27 positive patients in, 820  
   hypertrophic osteoarthropathy in, 902-906  
   onset of, 820  
   pauciarticular, 820-821  
 Childhood polyarthritis, 662  
 Chloroquine  
   in ankylosing spondylitis, 113-114  
   in RA, 113-114  
 Chondrocalcinosis, 94-95, 833  
 Chondrocyte, rat, *see* Rat chondrocyte  
 Chondromalacia patellae, 637-638  
 Chondromucoprotein, erosion of, 230  
 Chondroitin sulfate, 209, 212-214, 771, 1308  
 Chrysotherapy, 1321-1327  
   *see also* Gold salts  
 CIE, *see* Counterimmunoelectrophoresis  
 "Cigarette paper" scar, 763-766  
 Cigarette smoking, lung damage from, 627  
 Circulating immunoglobulins, in NZB/W nephritis, 46  
   *see also* Immunoglobulins  
<sup>14</sup>C-labeled *Staphylococcus aureus*, 618-619  
 Clayton operation, for feet, 31  
 Clinical Investigations Study Group on Rheumatic Diseases, 655  
 Clubbing  
   in childhood arthritis, 903-906  
   hypertrophic osteoarthropathy and, 643-644  
 Coagulation, intravascular, *see* Intravascular coagulation  
 Coagulation abnormalities, in rheumatoid disease, 1235-1239  
 Coal miners  
   pneumoconiosis in, 731-735  
   RA in, 731-735  
   serum immunoglobulin levels in, 734-735  
 Colchicine  
   dosage in, 620-621  
   in rheumatoid synovium, 69  
 Colchicine therapy  
   in familial Mediterranean fever, 618-621  
   skin-window test in, 620  
 Colitis, ulcerative, 660  
 Collagen  
   degradation of by superoxide radical, 799  
   incidence of antibodies to, 615  
   incubation of with collagenases in erythrocyte coupling, 614  
   loss of in cartilage destruction, 68-69  
   synthesis of by cartilage explants in vitro, 200  
 Collagenase, in human leukocytes, 829  
 Collagenase activity  
   enhancement of, 799  
   inflammation and, 203  
 Collagen biosynthesis, by human articular cartilage, 793

- Collagen chains, incidence of antibodies to, 615  
 Collagen production, lymphocyte factor stimulation of, 794  
 Collagen synthesis  
   fibroblasts in, 861  
   net protein and, 895-897  
   <sup>14</sup>C-proline incorporation in, 894  
 Committee for Evaluation of Medical Programs of the Arthritis Foundation, 34-35  
 Complement system, intraarticular activation of, in JRA, 161-166  
 Comprehensive Arthritis Centers, 29  
 Computer Committee, ARA, 645-647  
 Concanavallin A (con A), 509  
   in amyloidosis, 173, 179  
   in RA, 720-724  
 Concanavallin response, lymphocyte response to, 512, 875  
 Connective tissue activating peptide  
   in collagenase/protease production and release, 70  
   psoriasis and, 611  
 Connective tissue diseases, RA precipitin in, 713-714  
 Connective tissue synthesis, by cultured scleroderma fibroblasts, 891-900  
 Consultant rheumatologists, geographic distribution of in U.S., 56-58  
 Contraceptives, oral, and rheumatoid factor, 604  
 Convertase, in JRA, 161  
 Coombs' antibody, in NZB mice, 1354  
 Coombs' test, on NZB mice, 1348-1349, 1356  
 Copper, concentration of in rheumatoid patients, 597-598  
 Corticosteroid therapy  
   CPPD crystals and, 1369-1370  
   in NZB/W nephritis, 54  
   organic brain syndrome and, 1333-1337  
   in SLE, 79-81, 195-197  
*Corynebacteriaceae*, 41  
*Corynebacterium rubrum*, 41, 258  
 Coumadin therapy, in Hemarthrosis, 98-101  
 Counterimmunoelectrophoresis, 574-579  
   complement activation and, 787  
   vs hemagglutination, 579  
   identification of precipitins by, 578  
   mechanism of, 575-576  
   in Sjögren's syndrome, 578  
 CPPD crystals, *see* Calcium pyrophosphate dihydrate crystals  
 Creatine phosphokinase, in hypothyroidism, 1364-1365  
 CREST syndrome, 32  
 Critical electrolyte concentration reactions, cRNA, in *Erysipelothrix* arthritis, 39  
 Crohn's disease, 660  
   HLA antigens and, 662-663  
 Cryoimmunoglobulinemia, in Felty's syndrome, 103-109  
 Cryoglobulins, in Felty's syndrome, 106  
 Cryoprecipitates, lymphocytotoxic antibody activity in, 844-849  
 Cryoproteins, alternative complement pathway in, 829  
 Crystal shedding  
   in acute pseudogout, 93-97  
   calcium crystals in, 96  
   defined, 93-94  
   solubility studies in, 94  
 CTAP, *see* Connective tissue activating peptide  
 Cutaneous necrotizing venulitis, HLA genes and, 945-949  
   *see also* Angiitis  
 Cutaneous vessel immune deposits  
   antinuclear antibodies and, 16  
   biopsy specimens in, 16  
   fluorescein-conjugated antisera in, 16  
   frequency of, 16  
   laboratory tests in, 16  
   patient selection in, 16  
   in RA, 15-19  
 Cyclic AMP  
   interferon and, 1319  
   SLE serums and, 77  
 Cyclophosphamide  
   adverse effects of, 569  
   in autoimmune nephritis, 43  
   azathioprine and, 54  
   circulating DNA antibodies and, 52  
   delayed immune response and, 570-571  
   disease activity and, 565-567  
   dosage of, 53, 565  
   in lupus glomerulonephritis, 819  
   in lupus nephritis, 693-698  
   in NZB/W nephritis, 46, 49-54  
   onset and duration of drug effect in, 567-568  
   primary humoral immune response and, 570  
   in RA, 563-572  
   serum immunoglobulins in, 570  
   X-ray changes and, 568-569  
 Cystine, concentration of in rheumatoid patients, 597-599
- ## D
- dAT, *see* Polydeoxyribonucleotide  
 Degenerative arthritis, 65  
 Degenerative joint disease  
   smoking and, 624  
   synovitis in, 813  
 Dermatitis, azaribine and, 21, 27  
 Dermatitis herpetiformis, HLA-B8 and, 883  
 Dermatoglyphics, 83-86  
 Dermatomyositis  
   capillary microscopy in, 1370  
   counterimmunoelectrophoresis in, 578  
 Dibutyl adenosine cyclic 3':5'-monophosphate, 69  
 Diffuse interstitial fibrosis (DIF), 639  
 Digital arteritis, of hand, 19  
 2,4-dinitrochlorobenzene  
   immune response to, 563  
   in RA delayed immune response, 564-565  
 Discoid lupus erythematosus, 517-522  
   *see also* Systemic lupus erythematosus  
 Disodium EDTA, in CPPD crystal solubility, 94  
   *see also* EDTA  
 DJD, *see* Degenerative joint disease  
 DNA (deoxyribonucleic acid)  
   double stranded, 810  
   nephritis and, 49  
 DNA antibodies, in NZB/W nephritis, 50-53  
 DNA antibody, cryoglobulins and, 848  
 DNA-anti-DNA coated cells, in SLE, 797  
 DNA-anti-DNA complexes, in NZB/W nephritis, 49  
 DNA binding, in ds/ss heterogeneity, 810  
 DNA (dsDNA), antibodies to, 963-964  
 DNA synthesis, in amyloidosis, 179  
 DNA tolerance, in NZB/W mice, 826  
 DNCB, *see* 2,4-dinitrochlorobenzene  
 Dogs  
   experimental hemarthrosis of knee in, 59-66  
   RA in, 970-971  
 Down's syndrome, psoriatic arthritis and, 651  
 Drug abuse, rheumatic complication in, 923-926  
 Dysproteinemia, Sjögren's syndrome and, 1336
- ## E
- EBNA, *see* EBV-determined nuclear antigen  
 EBV, *see* Epstein-Barr virus  
 EBV-determined nuclear antigen, 717  
 Echo viruses, arthritis and, 1317  
 EDTA (ethylenediaminetetraacetate), in CPPD crystal solubility, 94



chelating abilities of, 96  
 gamma globulin viscosity increment and, 596  
 Ehlers-Danlos syndrome, 763-764, 767-768  
 EI, *see Erysipelothrix insidiosa*  
 Electron microscope studies  
   of immunoreactive cells in rheumatoid synovial membrane, 1-13  
   of perivascular accumulations, 3-5  
   of rheumatoid synovial membrane, 1-13  
 Emphysema, anticollagen antibodies in, 616  
 ENA, *see Extractable nuclear antigens*  
 Endocarditis  
   bacterial, *see Bacterial endocarditis*  
   subacute, 813-814, 889  
 Enzyme release, *see Lysosomal enzymes, release of*  
 Enzymes, collagenolytic system and, 69  
 Eosinophilia  
   fasciitis and, 792  
   morphea and, 792  
   scleroderma and, 792  
 Epidermal epithelial cells, in PSS, 969-970  
 Epon 812, 2  
 Epstein-Barr virus, 717  
 Erosive synovitis  
   adjuvant arthritis and, 257-259  
   *Erysipelothrix insidiosa* arthritis and, 256-257  
   mechanistic model of, 262-264  
   pathogenic model for, 256-264  
   streptococcal cell wall induced arthritis and, 260-261  
*Erysipelothrix* arthritis, 38, 262  
   DNA preparations in, 40  
   hybridization studies in, 40  
   immunohistology in, 40  
   nuclear acid hybridization in detection of, 38-42  
*Erysipelothrix insidiosa*, 38, 256-257  
   arthritis caused by, 256-257  
*Erysipelothrix* synovitis, 262  
 Erythrocyte sedimentation rate  
   cyclophosphamide and, 566-567  
   in relapsing polychondritis, 191  
*Escherichia coli*, arthritis and, 169, 171  
 Esophageal varices, in Felty's syndrome, 150-152  
 Essential hypertension, benign, 1259  
 Extracellular cathepsin D, detection of, 1304-1305  
   *see also Cathepsin D*  
 Extractable nuclear antigens, antibodies to, 851-856

## F

Factor II deficit, in SLE, 81  
 Familial Mediterranean fever  
   cutaneous inflammatory responses in, 619-620  
   lymphocyte studies in, 614  
 Fasciitis, eosinophilia and, 792  
 FDP, *see Fibrinogen degradation products*  
 Felty's syndrome  
   antinuclear antibody studies in, 104-106, 108  
   case report in, 150-151  
   circulatory immune complexes in, 108  
   clinical characteristics of, 105  
   cryoglobulins in, 104-107  
   cryoimmunoglobulinemia in, 103-109  
   esophageal varices in, 150-154  
   kidney reactive antinuclear factor in, 109  
   laboratory characteristics of, 105-106  
   patient population in, 104  
   SGOT level in, 153  
   splenectomy in, 150, 153  
   white cell abnormalities in, 108  
 Fenoprofen calcium, in gouty arthritis, 933-935  
 Fibrin, in skin immunoreactants, 17  
 Fibrinogen catabolism, in SLE, 195-198

Fibrinogen degradation products, 196-197  
 Fibrinogen metabolism, 198  
 Fibrinolysis, *see Intravascular coagulation and fibrinolysis*  
 Fibrin split products, in serum, 1239  
 Fibroblast degeneration, in rheumatoid synovitis, 6, 10  
 Fibroblasts  
   in collagen synthesis, 816  
   in scleroderma, 816-817  
 Fibrous myopathy, 923-926  
 Ficoll-Hypaque separated lymphocytes, in SLE, 89  
 Filtered *E coli* DNA, 868  
   *see also Escherichia coli*  
 Fine structure analysis techniques, 581-591  
 Fingers, clubbing of, 903-906  
 Fischer rat chondrocytes, *see Rat chondrocytes*  
 Floppy thumb sign, 243-244  
 Fluorescein-conjugated antisera, 16  
 Fluorescent band skin test, 792  
 FMF, *see Familial Mediterranean fever*  
 Freund's adjuvant, 259  
   *see also Adjuvant arthritis*  
 FSP, *see Fibrin split products*  
 Functional test, in RA, 1278, 1281-1285

## G

GAG, *see Glycosaminoglycans*  
 Gamma globulin  
   denaturation of, 593-599  
   human, *see Human gamma globulin*  
   inhibition of, 593-599  
 Gastrointestinal tract hemorrhage, in Felty's syndrome, 150-152  
*Genu amoris*, case report in, 637-638  
 Glomerular filtration rate, aspirin and, 159-160  
 Glomerulonephritis, 195  
 Glycol methacrylate  
   in adjuvant arthritis, 1340  
   kidney sections embedded in, 1344  
 Glycoprotein, in amyloidosis, 173  
 Glycosaminoglycans, of normal and OA cartilage, 209  
 Glycosaminoglycan synthesis  
   in hemarthrosis, 63-65  
   hexosamine and, 65  
 Gold and gold salts  
   *see also Chrysotherapy*  
   in ankylosing spondylitis, 113  
   British Anti-Lewisite in overdose of, 124  
   effectiveness of, 1323-1326  
   failures of, 1326  
   in kidney, liver, and spleen, 1368-1369  
   overdoses of in ventricular tachycardia, 1373-1374  
   in RA, 598, 796, 927, 1321  
   radioactive, *see Radiogold*  
   secretion of in mother's milk, 1374  
   side effects of, 1321-1322  
 Gold sodium thiomalate, 927, 1322-1328  
   inhibition of lymphocytes by, 808  
   synthesis of, 928  
 Gold toxicity, peritoneal dialysis and, 936-938  
 Gonococcal arthritis, low-dose penicillin therapy in, 826-827  
 Gout  
   hypothyroidism in, 123  
   renal tubular defect in, 828-829  
   tubular transport of urate in, 811  
 Gouty arthritis  
   fenoprofen calcium in, 933-935  
   indomethacin/aspirin in, 933  
 Gouty tophi, localization of immunoglobulin in, 802  
 Graves' disease, HLA-B8 and, 883  
 Group A streptococci, in Sydenham's chorea, 803  
 Guanidinium, proteoglycans and, 210-212



## H

Haida Indians, ankylosing spondylitis in, 1331-1332

### Hand

- deforming arthritis of, in polymyositis, 243-248
- digital arteritis in, 19
- immunoglobulins of, 19
- in Still's disease, 235-240

Hanks' balanced salt solution, 174

Heberden's nodes, pre-Columbian representation of, 125-126

Hemagglutination enhancement test, in RA, 612-615

Hemagglutination inhibition test, in RA, 614

### Hemarthrosis

- anticoagulant therapy in, 99
- atherosclerosis and, 98
- biochemical results in, 62
- biomechanical tests in, 60-63
- in canine knee joints, 59-66
- cartilage deformation in, 63-64
- case reports in, 98-100
- experimental, 59-66
- flexion deformities in, 60
- GAG content in, 64
- hemophilia and, 59
- heparin therapy in, 966
- hyperlipidemia and, 98
- as monoarthritis, 101
- morphology of, 60-62
- plasmacytomas and, 99
- sodium warfarin therapy in, 98-101
- vitamin K therapy in, 101

Hemochromatosis, 32

Hemophilia, hemarthrosis and, 59

Henoch-Schönlein purpura, IgA deposition in, 831

Henoch-Schönlein syndrome, 949

Herapin therapy, hemarthrosis secondary to, 966

Hepatic injury, salicylate-induced, 964-965

### Hepatitis

- drug abuse and, 923
- HLA-B8 antigen and, 803

Hepatitis B, research in, 31

Hereditary homozygous C2 deficiency, 517-522

Herpes virus, lymphocyte response to, 1269

Hexosamine, GAG synthesis and, 65

Hip abnormalities, radiologic findings in, 685

Hip involvement, in ankylosing spondylitis, 683-692

Hip surgery, bony reankylosis in, 691-692

### Histidine

- inhibitory effect of, 599
- viscosity increment and, 595

Histidine concentration, in RA, 593

Histidine-cystine-copper mixtures, in gamma globulin denaturation inhibition, 593-599

Histiocytic lymphoma, 252

Histochemical investigation, of adjuvant-induced arthritis, 1339-1345

Histocompatibility antigens, 656-657

see also HLA antigens

in SLE, 129-131

Histocompatibility complex, 657-658

### HLA antigens

see also Histocompatibility antigens

- in acute anterior uveitis, 660
- in ankylosing spondylitis, 659-660
- Behçet's disease and, 659
- cutaneous necrotizing vasculitis and, 945-949
- disease concept and, 661-662
- first international symposium on, 37
- mixed leukocyte reactions and, 532
- nonrheumatic diseases and, 658
- other genetic factors and, 659-660
- pairs of, 946
- peripheral arthritis and, 660-661

psoriasis and, 611

Reiter's disease and, 664

research in, 31

rheumatoid arthritis and, 537

in SLE, 129-131, 658

in sternomanubrial joint disease, 1372

HLA-A antigen, 657

HLA-All antigen, 947

HLA-B antigen, 657

HLA-B8 antigen

diseases associated with, 883-885

in Sjögren's syndrome, 811, 882-886

HLA-B27 antigen, 656-665

in ankylosing spondylitis, 804-805, 1326

in Pima Indians, 791

in seronegative arthritis, 795-796

HLA-BW35 antigen, 947

HLA-C antigen, 657, 659

HLA-D antigen, 657, 659, 661

in progressive systemic sclerosis, 749

HLA-haplotype 10, W18 antigen, 517-522

HOA, see Hypertrophic osteoarthropathy

HPO, see Hypertrophic pulmonary osteoarthropathy

Human gamma globulin

denaturation of, 593

histidine-cystine-copper mixtures and, 593-599

viscosity increment of, 595-596

Human lymphocytes, see Lymphocytes

Human synovial cells, hyaluronic acid production and, 1315-1318

Human synovial fluid, mononuclear cells in, 743-748

Humoral antibody response, in RA, 564

see also Antibodies

Humoral immune abnormalities, in amyloidosis, 173-180

### Hyaluronic acid

from human synovial fibroblasts, 1315-1319

interferon and, 1317-1319

overproduction of, 1316

rabbit synovial cells and, 70, 587-588

Hydroxychloroquine sulfate, lymphocytes and, 910

<sup>14</sup>C-Hydroxyproline, in scleroderma fibroblasts, 893

Hyperextensible joints, in Marfanoid hypermobility syndrome, 764-765

Hypergammaglobulinemia purpura, 949

Hyperlipidemia, hemarthrosis and, 98

Hyperostosis, ankylosing, of spine, 818

Hypersensitivity angitis, 949

Hypertension, tubular transport of urate in, 811

Hypertrophic pulmonary osteoarthropathy

in bronchogenic carcinoma, 629-635

clubbing and, 643-644

RA and, 639

secondary, 902-906

synovial effusions in, 633-634

Hyperuricosuria, benzbromarone and, 185

Hypocomplementemia, 837

fibrinogen consumption and, 195

in HLA antigens, 947

Hypothyroidism

gout and, 123

muscular weakness and, 1365

as polymyositis-like syndrome, 1363-1366

## I

### Ibuprofen

in acute polyarticular gout, 269

in RA, 791

ICF, see Intravascular coagulation and fibrinolysis

Idiopathic SLE, hydralazine therapy in, 122

see also Systemic lupus erythematosus

IgA antibody

in skin immunoreactants, 17  
 as primary homocytotrophic antibody, 671  
 in SLE, 671-672

IgG antibody  
 in LDAC studies, 146-148  
 in normal skin vessels, 18  
 opsonic activity reduction in, 77  
 rheumatoid factor and, 827  
 in skin immunoreactants, 17

IgG antilymphocyte antibodies, in SLE, 1261-1268

IgG galactose deficiency, in RA and SLE, 813

IgM antibody, in normal skin vessels, 18

IgM rheumatoid factor, 661

IgM-to-IgG switching, 819

Immune deposits, in cutaneous vessels, *see* Cutaneous vessel immune deposits

Immune synovitis, osmic acid in, 737-742

Immunofluorescence microscopy, in RA, 557

Immunofluorescence test, in rat chondrocyte antigen profile, 225-227

Immunoglobulin light chain, in primary amyloidosis, 755-758

Immunoglobulins  
 deposit of in cutaneous vessels, 15-19  
 glomerular deposition of, 1356  
 in SLE, 670-671

Immunoreactive cells in rheumatoid synovial membrane, 1-13

Indirect hemagglutination test, 649

Indomethacin, 907  
 aspirin and, 933  
 lymphocytes and, 910, 915  
 in pseudogout, 95

Inflammation  
 lysosomal enzymes in, 73, 203-206  
 phagocytic cells in, 73  
 in RA, 68  
 in rabbit articular cartilage metabolism changes, 199-207

Inflammatory arthritis, hip involvement in, 689

Inflammatory myopathy, myoglobinemia in, 804

Inflammatory process, *see* Inflammation

Interferon  
 cyclic AMP and, 1317  
 in rheumatoid synovial fluids, 1317-1319

Intervertebral disk degeneration, 817

Intravascular coagulation and fibrinolysis  
 overcompensated, 1240-1241  
 in RA, 1237-1241

Intravascular drug abuse, fibrous myopathy and, 923-926

## J

Joint destruction, irreversible, 68

Joint dislocation, in neuropathic arthropathy, 1365-1366

Joint lavage, in chondrocalcinosis of knees, 93-94

Joint replacement, synovial debris following, 793

Joseph J. Bunim Memorial Lecture, 655-665

JRA, *see* Juvenile rheumatoid arthritis

Juvenile rheumatoid arthritis  
 amyloid protein SAA in, 789  
 ankylosis and, 240  
 cataracts in, 788  
 complement system intraarticular activation in, 161-166  
 hip joint restoration in, 789-790  
 pericardial tamponade in, 760-762  
 serum complement values in, 164-165  
 serum glutamate oxaloacetic transaminase in, 115-118  
 serum glutamic pyruvic transaminase in, 115-118  
 serum immunoglobulin levels in, 165-166  
 SLE and, 115-118  
 synovial fluid values in, 162-163  
 tolmetin and aspirin in, 807  
 transaminase and serum salicylate concentrations in, 115-118

## K

Keitel functional test, 1278-1285

Keratan sulfate, 209

Ketoprofen, in RA, 791

Kidney, gold levels in, 1368-1369

Killer cell  
 character of, 135  
 in LDAC system, 133-134, 138-139

Kininogen, in JRA, 161-166

Knee  
 arthritis of, 637-638  
 arthrocentesis of, 234  
 cathepsin D localization in, 1295-1305  
 chondrocalcinosis of, 93  
*Mycobacterium intracellulare* infection of, 777-780  
 osteoarthritic cartilage of, 209-214

Knee joints  
 hemarthrosis of, 98-101  
 rabbit, *see* Rabbit knee joint  
 torn medial meniscus and, 99

Kupffer cells, gold distribution in, 927-928

## L

Lactate formation, in synovial cells, 70

Lactic dehydrogenase, in hypothyroidism, 1365

Lactoferrin-to-lysosome ratio, in synovial fluid, 789

Lansbury articular index, 1278

Large mononuclear cells, in synovial fluid, 743-748

Latex, in proliferative lesions, 69

LBT, *see* Lupus band test

LDAC, *see* Lymphocyte-dependent antibody cytotoxicity

LE cells, in lungs, 249-252  
*see also* Systemic lupus erythematosus

Leech hyaluronidase, proteoglycan digestion by, 1309

Leg ulcers, in RA, 18

Leukemia-lymphoma, amyloidosis and, 174-177

Leukocyte reaction, mixed, *see* Mixed leukocyte reaction

Leukocyte migration inhibition test, 540, 543

Leukocyte pyrogen production, colchicine and, 619

Leukocyte response, to synovial RA extracts, 798  
*see also* Mixed leukocyte reaction

Leukocytes  
 latent collagenase activation in, 829  
 lysosomal enzyme release in, 74

Leukocytic protein, production of, 618

Linear variable displacement transducer, 60-61

*Listena monocytogenes*, 38

Lithium heparin crystals, in CPPD crystals, 966-967

Liver, gold levels in, 928, 1368-1369

Liver enzymes, salicylates for, 267-268

Liver function, aspirin and, 155-160

LKB microtome, 2

LL, *see* Leukemia-lymphoma

LMN, *see* Large mononuclear cells

Lungs  
 in RA, 732  
 in SLE, 249-252

Lupus anticoagulant, 1244-1246  
 antibody nature of, 1246

Lupus band test, 1249-1254

Lupus erythematosus  
*see also* Systemic lupus erythematosus  
 amyloidosis and, 249-252  
 discoid, *see* Discoid lupus erythematosus  
 lymphoproliferative disease and, 251  
 in pleural fluid, 962-963

Lupus glomerulonephritis  
 cyclophosphamide and azathioprine in, 819  
 defined, 833

Lupus nephritis  
*see also* SLE  
 L-asparaginase treatment of, 810  
 complement-fixing antinuclear antibodies in, 857-860  
 double-blind crossover trial in, 695  
 prednisone-azathioprine-cyclophosphamide in treatment of, 693-698

LVDT, *see* Linear variable displacement transducer

Lymph nodes, immunologic stimulation of, 252

Lymphoblasts  
 in rheumatoid synovitis, 7  
 in synovial fluid, 745-747

Lymphocyte activity, in RA, 509-515

Lymphocyte-dependent antibody cytotoxicity, 133-140  
 B-cell subpopulation in, 138  
 gel filtration experiments in, 143-145  
 inhibition of, 135-136, 138-140  
 killer cell in, 133, 135, 138-139  
 measurement of, 134  
 in patients with RA and SLE, 136-138  
 preincubation experiments in, 145-147  
 serum inhibitors of, 142-149  
 synovial fluid inhibitors of, 142-149  
 stimulation of collagen production and, 794

Lymphocyte fractionation, in LDAC testing, 134

Lymphocyte populations, in RA, 720-724

Lymphocyte responsiveness  
 in ankylosing spondylitis, 798  
 modification of by complement, 806  
 in progressive systemic sclerosis, 875-881  
 in scleroderma, 805  
 in SLE, 88-91

Lymphocytes  
 antirheumatic drugs and, 907-916  
 "effector" roles of, 258  
 infiltration of rheumatoid synovium by, 1  
 inhibition of by gold sodium thiomalate, 808  
 in vitro immunoglobulin synthesis of, 830  
 mitogen-stimulated, 744, 1265-1267  
 peripheral blood, *see* Peripheral blood lymphocytes  
 in perivascular accumulations, 6-8  
 in RA, 523  
 Type C virus related antigens and, 809  
 viability of, 911

Lymphocyte transformation, in amyloidosis, 176

Lymphocytic antibodies, in SLE patients and relatives, 700-703

Lymphocytic choriomeningitis, 657

Lymphocytotoxic antibodies  
 in cryoprecipitates from SLE patients, 844-849  
 in SLE, 546-549, 817-818

Lymphocytotoxicity  
*see also* Lymphocyte-dependent antibody cytotoxicity  
 antibody-mediated, 133-140  
 in RA, 133-140  
 in SLE, 133-140  
 suppression of in SLE, 831

Lymphokine(s), in RA, 70

Lymphokine-like substances, in synovial fluid, 10

Lymphokine production, in SLE, 794

Lysosomal enzymes  
 inflammation and, 203-206  
 PMN and, 74-75  
 reduction of in SLE, 73-77  
 stimulation of, by carrageenin, 1291-1292

Lysosomes, gold distribution in, 928

## M

Macrophage phagocytosis, serum and granuloma protein inhibitors of, 790

Macrophages, in rheumatoid synovitis, 8-10

MAK chromatography, 867

Mandible  
 bone erosion of, in scleroderma, 1369  
 resorption of, in vinyl chloride acro-osteolysis, 971

Marfan syndrome, 763, 766-768

Marfanoid hypermobility syndrome, cardiovascular abnormalities in, 763-768

Maternal milk, gold secretion in, 1374

Maximal midexpiratory flow rates, in pulmonary disease, 624-626

MCTD, *see* Mixed connective tissue disease

Measles, lymphocyte response to, 1271

Medical Administrative Committee, Arthritis Foundation, 29-30

Mediterranean fever, familial, 618-621

Membrane receptor studies, of rabbit synovial cells, 587-588

Meperidine, abuse of, 923

6-Mercaptopurine, in psoriasis, 28

Metabolic inhibition technique, 1326-1330

Metacarpophalangeal joints, ankylosing spondylitis of, 111-112

Metatarsophalangeal joints, ankylosing spondylitis of, 111

*d*-2-(6'-methoxy-2'-naphthyl)propionic acid, *see* Naproxen

Methylated albumin-Kieselguhr chromatography, 867

Methylprednisolone, in NZB/W nephritis, 46

Mice, NZB/W, *see* NZB/W mice

$\beta$ 2-Microglobulin, SLE and, 968

Midline granuloma, nasal septum perforation in, 119

MIF (melanocyte-stimulating hormone inhibitory factor), in synovial fluid, 10-13

MIT, *see* Metabolic inhibition technique

Mitogen responses, in SLE twin studies, 548-550

Mitogens  
*see also* Concanavallin A; Phytohemagglutinin P  
 lymphocyte responsiveness to, 509-514  
 in progressive systemic sclerosis, 875-881

Mitogen stimulation  
 lymphocytes and, 1265-1267  
 in SLE, 827-828

Mixed connective tissue disease, 32  
 antibodies to nuclear antigens in, 574  
 in children, 788, 822  
 complement-fixing antinuclear antibody in, 857-860  
 extractable nuclear antigens and, 851-856  
 nasal septum perforation in, 119-121  
 precipitin identification in, 578  
 pulmonary involvement in, 801  
 ribonucleoprotein and, 851

Mixed cryoglobulinemia, nasal septum perforation in, 119-121

Mixed leukocyte cultures, in SLE twin studies, 546, 549

Mixed leukocyte reaction  
 in autologous serum, 535  
 in RA, 532-537  
 salicylate effect in, 536

Mixed lymphocyte culture  
 in HLA typing, 657, 659  
 3HTdR uptake and, 911-912

MLC, *see* Mixed leukocyte culture; Mixed lymphocyte culture

MLR, *see* Mixed leukocyte reaction

MM, *see* Multiple myeloma

Mnemonics, use of, 650-651

Monarthritis, hemarthrosis as, 101

Monoclonal immunoglobulins, in amyloidosis, 173

Monocytes, in synovial fluid, 745-747

Mononuclear cells  
 in human synovial fluid, 743-748  
 large, 743-748  
 normal, 745  
 in SLE, 89

Monosodium urate crystals  
 immunoglobulin and, 802  
 protein adsorption to, 805

Morning stiffness, 1283  
 Morphea, eosinophilia and, 792  
 MSU, *see* Monosodium urate  
 Multiple myeloma, amyloidosis and, 174-177  
 Multiple sclerosis, hereditary C2 deficiency in, 521  
 Mumps, arthritis and, 1317  
 Murine amyloid, protein AA and SAA in, 822-823  
 Murine NZB/W disease, *see* NZB/W nephritis  
 Myasthenia gravis, HLA-B8 and, 883  
*Mycobacterium avium*, 777  
*Mycobacterium bovis*, 777  
*Mycobacterium intracellulare*, chronic arthritis due to, 777-780  
*Mycobacterium kansasii*, 779  
*Mycobacterium leprae*, 777  
*Mycobacterium tuberculosis*, 777  
*Mycoplasma hyorhinus*, 41  
*Mycoplasma spp.*, 649-650  
 Myochrysine, 927  
 Myoglobinemia, in inflammatory myopathy, 804  
 Myopathy, inflammatory, 804  
 Myositis ossificans, 925  
 Myxedema heart disease, 1365

## N

Nailfold capillary microscopy, 1370  
 Naprosyn, 677  
 Naproxen, 907  
 Naproxen-aspirin combination therapy  
   efficacy, evaluation of, 678-680  
   premature discontinuation of, 678  
   in RA, 677-681  
   tolerance to, 680  
 Nasal septum perforation, in rheumatic diseases, 119-121  
 National Advisory Committee on the Future of Arthritis Research, 31-32  
 National Arthritis Act of 1975, 29, 645  
 National Commission on Arthritis, 29  
 National Institute of Arthritis and Metabolic Diseases, 655-656  
 National Institutes of Health, 30-31, 655  
 Neoplasia, in RA and SLE, 1256-1260  
 Nephritis  
   autoimmune, 43  
   lupus, 810  
 Neuropathic arthropathy, joint dislocation in, 1367-1368  
 Neutrophil elastase, 627  
 Neutrophilic functions, pregnancy-associated serum factor in, 815-816  
 Neutrophil migration  
   colchicine therapy and, 620  
   in vitro, 619  
 New Zealand black/white mice, *see* NZB/W mice  
*Nocardia asteroides*, 258  
 Nonimmune rabbit serum, in cathepsin D localization, 1297-1303  
 Nonimmune sheep serum, in cathepsin D localization, 1297-1303  
 Nonrheumatic diseases, HLA antigens in, 658  
 Nuclear acid protein, antibody detection and, 574-576  
 Nuclear antigens, extractable, 851-856  
 Nuclear ribonucleoprotein, in Sjögren's syndrome, 576  
 Nucleic acid, *see* DNA; *see also* RNA  
 Nucleic acid hybridization  
   detection and semiquantitation of tissue microorganisms by, 38-42  
   materials and methods in, 38-39  
 NZB/W mice  
   antinuclear antibody in, 1354-1355  
   autoimmunity suppression in, 1347-1349  
   Coombs' antibody in, 1354  
   Coombs' test in, 1348-1349, 1356

in cyclophosphamide studies, 50  
 DNA-anti-DNA complexes in, 49  
 DNA tolerance in, 826  
 immunoglobulin classes and subepidermal deposits in, 797  
 kidney tissue in, 45  
 lupus nephritis in, 810  
 mortality in, 1355  
 polyriboadenylic binding in SLE of, 705-709  
 renal histopathology in, 1315-1316  
 SLE in, 693, 705-709  
 therapeutic studies in, 43-48  
 thymocyte-treated, 1347-1349  
 transfer of spleen cells in, 1353-1357  
 NZB/W nephritis, 43-48  
   azathioprine in, 46  
   corticosteroids in, 54  
   cyclophosphamide in, 46, 49-54  
   DNA antibodies in, 50-53  
   methylprednisolone in, 46

## O

OA cartilage, *see* Osteoarthritic cartilage  
 OAF, *see* Osteoclast activating factor  
 OBS, *see* Organic brain syndrome  
 Obstructive pulmonary disease, in RA, 623-627  
 OC, *see* Oral contraceptives  
 Oral contraceptives, side effects of, 602-606  
 Organic brain syndrome  
   Sjögren's syndrome and, 1334  
   SLE and, 1336  
   treatment and response in, 1335  
 Organizing Committee for Pediatric Rheumatology, 36  
 Osmic acid, in immune synovitis, 737-742  
 Osteoarthritic cartilage  
   cathepsin D type enzyme in, 205  
   collagen content of, 199  
   ground substance proteoglycans in, 209-214  
   other proteoglycans from, 1308-1314  
 Osteoarthritis  
   fenoprofen in, 933  
   fundamental defect in, 209  
   joint destruction in, 199  
 Osteoarthropathy  
   hypertrophic pulmonary, *see* Hypertrophic pulmonary osteoarthropathy  
   secondary hypertrophic, 902-906  
 Osteoclast activating factor, 70  
 Osteophytosis, in ankylosing spondylitis, 686-688  
 Osteoporosis, polymyositis and, 244  
 Ouchterlony studies, in RA, 713  
 Ovarian failure, cyclophosphamide-induced, 693  
 "Overlap syndrome," in polymyositis, 245-246, 248

## P

PA, *see* Primary amyloidosis  
 Panmesenchymal reaction, 1335-1336  
 Pannus/cartilage junction, intracellular collagen at, 801-802  
 Pannus cells, primary culture of, 69  
 Parainfluenza, lymphocytic response to, 1271  
 Paraproteinemia, monoclonal, 959  
 Parathyroidectomy, pseudogout and, 96  
 Partial thromboplastin time, lupus anticoagulant and, 1244  
 Patellar scraping, in hemarthrosis, 99  
 Pauciarticular childhood arthritis, 820-821  
 PBL, *see* Peripheral blood lymphocytes  
 P-component  
   amino acid analyses and, 752-753  
   in plasma, 753  
   sequencing and, 253



- Pemphigus, gold compounds in, 927
- Penicillamine, in ankylosing spondylitis, 122
- Penicillin G, in articular cartilage, 828
- Pentazocine, abuse of, 923, 925
- Peptidoglycan, streptococcal, 260
- Percodan therapy, in hepatic injury, 965
- Pariarteritis nodosa, 949
- Periarticular synovium, removal of, 1300
- Pericardial tamponade, in JRA, 760-762
- Pericardiocentesis, 761-762
- Pericarditis, 1335
  - infectious, 761
- Periodic acid Schiff reaction, 1340
- Peripheral blood lymphocytes
  - antirheumatic drugs and, 907-916
  - blastogenic transformation of, 509
  - mitogenic responses of to autologous cells, synovial fluid, and phytohemagglutinin, 526-529
  - responsiveness of to synovial fluid cells, 525
  - transformation of by autologous synovial fluid lymphocytes, 523-530
- Peripheral neuritis, 1335
- Peritoneal dialysis, gold toxicity and, 936-938
- Peritoneal immunoglobulin light chain, in primary amyloidosis, 755-758
- Perivascular cells, in transitional area, 13
- Perivascular cellular accumulations
  - cell counts in, 3-5
  - electron microscope findings in rheumatoid synovitis, 3
  - lymphocytes in, 6-8
  - perivascular collections in, 8
  - in rheumatoid synovitis, 3-4
  - three types of, 8
- PGE, *see* Prostaglandin E<sub>2</sub>
- PGs, *see* Proteoglycans
- PHA, *see* Phytohemagglutinin
- Phagocytosis
  - in familial Mediterranean fever, 619
  - reduction of, 73-77
- PHA mitogens
  - response of whole blood cultures to, 1273
  - in SLE, 89
- Phenylbutazone, lymphocytes and, 907, 909-915
- Phosphoribosylpyrophosphate content, benzbromarone and, 184, 188-189
- PHS, *see* Pooled human serum
- Phytohemagglutination, antibody identification in, 575
- Phytohemagglutinin, in amyloidosis, 173
  - lymphocyte response in, 509-511, 525-527, 875, 912-913, 1266-1267
  - in RA, 720
- Pima Indians, HLA-B27 antigen and sacroiliitis in, 791
- Pi phenotypes, in RA, 627
- Plant thorn synovitis, 825
- Plasma, fibrinogen levels in, 1240
- Plasmablasts, in rheumatoid synovitis, 8
- Plasma cells, infiltration of rheumatoid synovium by, 1
- Plasmacytomas, hemarthrosis and, 99
- Pleuritis, 1335
- PMF, *see* Progressive massive fibrosis
- PML, *see* Progressive multifocal leukoencephalopathy
- PMN, *see* Polymorphonuclear leukocytes
- Pneumoconiosis
  - in coal miners, 731-735
  - "complicated," 732
  - frequency and severity of, 733-734
- Pokeweed mitogen
  - antilymphocyte antibody activity of, in SLE, 1266-1268
  - lymphocyte responses to, 509, 512-513
- Polyarteritis, drug abuse and, 923
- Polyarthritis
  - carcinomatous, 953-957
  - in childhood, 808
- Polychondritis, relapsing, 32, 229
- Polydeoxyribonucleotide, antibodies to, 867-872
- Polyinosinic-polycytidylic acid, interferon and, 1315-1319
- Polymixin B, in articular cartilage, 828
- Polymorphonuclear leukocytes, 73
  - in adjuvant arthritis, 1340-1345
  - chemotaxis of, 825-826
  - CPPD crystals in, 95
  - lysosomal enzymes in, 830
  - phagocytic capacity of, 77
  - release of proteolytic enzymes from, 68-69
  - in SLE, 73
- Polymyalgia rheumatica, 32
  - joint imaging in, 815
- Polymyositis
  - antinuclear antibody in, 830
  - arthralgias in, 243, 245
  - deforming arthritis of hands in, 243-248
  - diagnosis of, 245
  - osteoporosis and, 244
  - "overlap syndrome" in, 245-246, 248
- Polymyositis-like syndrome, hypothyroidism as, 1363-1366
- Polyriboadenylic acid, antibody binding of in SLE, 705-709
- Pooled human serum, 532
  - mixed leukocyte reaction in, 534-535
  - rheumatoid, lymphocyte response in, 536
- PPD antigens, in SLE, 89
- PPH, *see* Protocollagen proline hydroxylase
- Prednisolone, virus antigens and, 1274
- Prednisone, in ankylosing spondylitis, 111
- Prednisone-azathioprine, in lupus nephritis treatment, 693-698
- Pregnancy
  - azaribine and, 28
  - rheumatoid arthritis and, 602
- Pregnancy-associated serum factor, 815-816
- Primary amyloidosis, 174-175
  - see also* Amyloidosis
  - immunoglobulin light chain in, 755-758
- Progressive systemic sclerosis, nasal septum perforation in, 119-121
- Progressive massive fibrosis, 732
- Progressive multifocal leukoencephalopathy, 267
- Progressive systemic sclerosis, 216, 246
  - see also* Scleroderma
  - counterimmunoelectrophoresis in, 574, 578
  - epidermal epithelial cell growth in, 969-970
  - HLA-D antigen in, 794
  - lymphocyte response to mitogens in, 875-881
  - skeletal muscle abnormalities in, 807-808
- Proliferative lesion, in RA, 68-71
- <sup>14</sup>C-Proline, determination of in scleroderma fibroblasts, 893
- <sup>3</sup>H-Proline, in cartilage explants, 206
- <sup>3</sup>H-Proline-labeled collagen, in rabbit articular cartilage, 204
- Pronase, 927
- Properdin factors, in JRA, 161-166
- Prophylactic colchicine therapy, in familial Mediterranean fever, 618-621
- Prostaglandin E<sub>2</sub>, 31
  - rheumatoid synovial tissue and, 70
- Prostaglandin synthesis, corticosteroid inhibition of, 818-819
- <sup>125</sup>I Protein A, IgG antilymphocyte antibody detection of, 1261-1268
- Protein AA, in murine amyloid, 822-823
- Protein adsorption, to monosodium urate crystals, 805
- Protein SAA, in murine amyloid, 822-823
- Proteoglycans, 1310-1314
  - amino acid composition of, 212
  - from bovine cartilage, 1312
  - cartilage, *see* Cartilage proteoglycans
  - chondroitin sulfate chains of, 214
  - constituents of, 209



depletion of from articular cartilage, 68  
 enzymic digestion and, 1288  
 extract preparation from, 1288, 1310  
 guanidinium in extraction of, 212-213  
 hyaluronate-binding region on, 1308-1314  
 isolation of, 1309-1310  
 in normal and osteoarthritic knee cartilage, 209-214  
 proteolytic degradation of, 1289-1290  
 synovial fluid and, 772  
 synthesis of in articular cartilage, 918-921  
 Proteolytic enzymes, in synovial tissue extracts, 1289-1291  
 Prothrombin time, lupus anticoagulant and, 1244  
 Protocollagen proline hydroxylase, 891-892  
 PRPP, *see* Phosphoribosylpyrophosphate  
 Pseudogout, 32  
   crystal shedding and, 93-97  
   defined, 93  
   indomethacin and, 95  
   lavage procedure in, 94  
   parathyroidectomy and, 96  
   postoperative acute attack of, 97  
   predisposing events in, 96  
 Pseudomonas aeruginosa, 169  
 Psoriasis  
   ankylosing spondylitis and, 660  
   chronic peripheral arthritis and, 662  
   connective tissue activating substance and, 611  
   DNA content of, 612  
   genetic factors in, 663  
   HLA antigens in, 611  
   <sup>99m</sup>Tc diphosphonate uptake in, 607-612  
 Psoriatic arthritis, 661, 663  
   *see also* Azaribine  
   azaribine in, 21-28  
   Down's syndrome and, 651  
   6-mercaptopurine in, 28  
   nasal septum perforation in, 119-121  
 PSS, *see* Progressive systemic sclerosis  
 Pulmonary disease, maximal midexpiratory flow rates in, 624-626  
 Pulmonary embolus, following patellar scraping, 99-100  
 Pulmonary fibrosis, hypertrophic osteoarthropathy and, 643  
 Pulmonary involvement, in mixed connective tissue disease, 801  
 Pulmonary lesions, in RA patients, 623  
 Pulmonary osteoarthropathy, hypertrophic, *see* Hypertrophic pulmonary osteoarthropathy  
 Purine biosynthesis, benzbromarone and, 189  
 Purine phosphoribosyltransferase, benzbromarone and, 184  
 Purine synthesis, benzbromarone in, 183  
 Purpura, *see* Henoch-Schönlein purpura  
 PVP hemagglutination test, in rat chondrocyte antigen studies, 224  
 PWM in SLE, 89  
   *see also* Pokeweed mitogen

## Q

Quinidine, hemarthrosis and, 100

## R

RA, *see* Rheumatoid arthritis  
 Rabbit articular cartilage, metabolic changes in due to inflammation, 199-207  
 Rabbit knee joint, 770-771  
   carrageenin injection in, 1287  
   proteolytic enzymes in, 1287-1293  
 Rabbits, osmic acid treatment in, 740  
 Rabbit synovial cells  
   acid phosphatase and, 1292  
   explant cultures of, 584-586

fibroblast population of, 588  
 fine structure analysis of, 581-591  
 hyaluronic acid production and, 587  
 inflammatory response in, 739-740  
 membrane receptor studies and, 586-588  
 monolayer cultures of, 587-588  
 rosette forming cells and, 582-584, 589-591  
 Radiogold, intracellular distribution of, 927-931  
 Radionuclide imaging, in <sup>99m</sup>Tc diphosphonate uptake, 608  
 RAI, *see* Ritchie articular index  
 RAP, *see* Rheumatoid arthritis precipitin  
 Rat chondrocyte  
   antigen profile of, 223-230  
   hemagglutinating bodies produced by, 225  
   in tissue culture, 228  
 Rat liver xanthine oxidase activity, benzbromarone in, 183  
 Raynaud's phenomenon, 243-244  
   biofeedback in, 795  
   polymyositis and, 246-247  
   vinyl chloride and, 809  
 Reactive arthritis, 664-665  
 Regional Medical Programs Arthritis Conference, 645  
 Reiter's disease, 660-661, 665, 747  
   adjuvant arthritis and, 1339  
   following urethritis, 664  
   HLA antigens and, 664, 883  
   postdysenteric, 664  
   T mycoplasma antibody and, 1332  
 Relapsing polychondritis  
   arthropathy and, 191-194  
   autoimmune mechanism in, 229  
   case report in, 192-193  
   defined, 191  
   RA and, 193  
 Renal disease, in SLE, 196, 806  
 Renal tubular defect, in gout, 828-829  
 Research and training programs, 32-33  
 Research grants, 32  
 Rheumatic diseases  
   chronic effects of, 907  
   federal support for research in, 30  
   HLA antigens and, 658-659  
   inheritance of, 656-665  
   oral contraceptives and, 602  
   perforation of nasal septum in, 119-121  
   "recent," 32  
   susceptibility to, 656-665  
   uniform database for, 645-648  
 Rheumatic fever, HLA antigens and, 658-659  
 Rheumatoid arthritis  
   *see also* Rheumatoid factor  
   agammaglobulinemia and, 555  
   altered lymphocyte reactivity in, 509-515  
   antibodies to native and denatured collagens in, 613-616  
   antibody-dependent cell-mediated cytotoxicity in, 725-729  
   antibody-mediated immunity in, 555  
   anti-gamma globulins in, 613  
   antigen-antibody complexes in, 613  
   antinuclear antibodies in, 712  
   antisera and fluorochrome conjugates in, 556  
   antitrypsin phenotypes in, 627  
   articular surface erosion in, 769  
   aspirin in, 155-160  
   avian reovirus arthritis as model of, 830  
   azathioprine in, 795  
   blood gold concentrates in, 598  
   blood histidine concentration in, 593  
   blood L lymphocytes in, 802-803  
   carpo/metacarpal ratio in, 939-944  
   cell-mediated immunity to IgG in, 828  
   cellular hypersensitivity in, 539-543  
   chloroquine in, 113-114

- chrysotherapy in, 1321-1327
- circulating anticollagen and anti-IgG autoantibodies in, 539
- in coal miners, 731-735
- coexistence with ankylosing spondylitis, 111-114
- combination therapy in, 677-681
- concanavallin A and, 720-724
- corticosteroid treatment in, 1331-1335
- counterimmunoelectrophoresis in, 574, 578
- cryoglobulins in, 103
- cutaneous vessel immune deposits in, 15-19
- cyclophosphamide in, 563-572
- deficient cell-mediated immune responses in, 807
- degenerative joint disease in, 627
- delayed immune response in, 564-565, 570-571
- dermal vessels in, 16
- disease activity measures in, 565-567
- in dogs, 970-971
- erythrocyte sedimentation rate in, 566-567
- etiology of, 555
- extraarticular vasculitis in, 18
- Felty's syndrome in, 150
- fenopufen in, 933-935
- free blood amino acid in, 593
- functional test in, 1278-1280
- gamma globulin denaturation in, 593-599
- gold salts in, 113-114, 796, 927, 1321
- hemagglutination enhancement test and, 614
- histidine, cystine, and copper concentrations in, 597-599
- humoral antibody response in, 564
- hypertrophic osteoarthropathy and, 639-644
- ibuprofen in, 791
- ICF in, 1237
- identification of B and T lymphocytes in, 556
- IgG galactose deficiency in, 813
- IgG immunity in, 828
- immune complexes in, 788
- immunofluorescence microscopy in, 557
- immunologic mechanisms in, 223
- inflammatory process in, 68
- intracellular collagen at pannus/cartilage junction in, 801-802
- joint destruction in, 199
- juvenile, *see* Juvenile rheumatoid arthritis
- ketoprofen in, 791
- LDAC and, 142-149
- leg ulcers in, 18
- leukocyte responses to, 798
- Levamisole in, 807
- lungs in, 732
- lymphocytes in, 523, 720-724
- lymphocytotoxicity in, 133-140
- lymphoid hyperplasia in, 523
- lymphokines in, 70
- measurements in, 1278-1284
- mixed leukocyte reaction in, 532-537
- morning stiffness in, 1281-1282
- Mycoplasma* strains in, 649-650
- naifold capillary microscopy in, 1370-1371
- Naproxen with aspirin in, 677-681
- nasal septum perforation in, 119-121
- neoplasia in, 1256-1260
- obstructive pulmonary disease in, 623-627
- organic brain syndrome and, 1333-1337
- parenchymal pulmonary lesions in, 623
- pericarditis and, 760
- Pi phenotypes in, 627
- pleuropulmonary manifestations in, 623
- pneumonoconiosis and, 731-735
- polyarthritis and, 953
- polymorphonuclear cells in, 774
- pregnancy and, 602
- primary humoral immune response in, 570
- proliferative lesion in, 68-71
- relapsing polychondritis and, 193
- seronegative, 814
- seropositive, 16
- serum antibody vs cell-associated antigen in, 711-718
- serum immunoglobulins in, 570, 731-735
- Sjögren's syndrome and, 216, 712
- skin immunoreactants in, 17
- sodium aurothiomalate in, 802
- subtypes of, 711-712
- sural nerve biopsies in, 823
- synovial collagenase and, 69
- synovial fluid in, 744
- synovial inflammation in, 769
- synovial membrane in, 581, 737
- synovitis in, 539
- thrombocytosis in, 793
- T-lymphocyte predominance in, 555-561
- vasculitis and, 15-19, 1237
- wrist involvement in, 112-113, 939-944
- wrist prosthesis in, 828
- X-ray changes in, 568-569
- Rheumatoid arthritis precipitin, 216, 714-715, 787
  - as antibody, 717
  - characterization of, 713
  - immunoglobulin nature of, 716
  - prevalence of in connective tissue diseases, 713-714
  - RA antigen and, 220-221
  - rheumatoid factor and, 219-220
  - in synovial fluid, 718
- Rheumatoid arthritis precipitin antigen, protein molecule as, 717
- Rheumatoid disease, coagulation abnormalities in, 1237-1241
  - see also* Rheumatoid arthritis; Rheumatoid factor
- Rheumatoid factor
  - see also* Rheumatoid arthritis
  - in acute bacterial endocarditis, 887-890
  - in coal miners, 732
  - in choroid plexus, 1336
  - cyclophosphamide and, 569-570
  - IgG interactions with, 827
  - IgM type, 661
  - inconstancy of, 605
  - oral contraceptives and, 604
  - organic brain syndrome and, 1335
  - in women, 602-606
- Rheumatoid patients, cathepsin D in tissues of, 1295-1305
- Rheumatoid pericarditis, 760-762
- Rheumatoid serum, mixed leukocyte reaction and, 535-536
- Rheumatoid synovial cells, cell growth inhibitor in, 823
- Rheumatoid synovial collagenase, release and activation of, 809
- Rheumatoid synovial membrane, immunoreactive cells in, 1-13
- Rheumatoid synovitis
  - blast cells in transitional areas of, 5-6
  - cell counts in, 3-5
  - electron microscope findings in perivascular cellular accumulations of, 3
  - fibroblast degeneration in, 10
  - light microscope findings in sublining area of, 2-3
  - lymphoid cell macrophage contact in transitional areas of, 6
  - perivascular cellular collection in, 3-4
  - T and B cells in, 8-10
  - vasculitis in, 18
- Rheumatoid synovium
  - cell specimens in, 557-559
  - cellular immune response in, 10
  - colchicine and, 69
  - immunologic responses of, 1
  - living cells from, 70
  - lymphocytes and plasma cells in, 1, 6-8
  - prostaglandin synthesis by, 70, 818-819

- sublining area of, 6
- T and B lymphocytes in, 556-559
- transitional areas in, 8
- Rheumatoid ulcers, 18-19
- Rheumatoid vasculitis, 15-19, 950-951
- Rheumatologists, consultant, in U.S., 56-58
- Rheumatology, organizations involved in, 655
- Rheumazahl index, 1282
- Rh factor negative, 814
- Ribonucleoprotein, nuclear, 574
- Ritchie articular index, 1278-1279, 1281, 1283-1284
- RNA-DNA hybridization, in detection of *Erysipelothrix* arthritis, 38-42
- Rosette forming cells, in rabbit synovial membrane, 582-584, 589-591
- RP, *see* Relapsing polychondritis
- Rubella
  - arthritis and, 1317
  - lymphocyte response to, 1271
  - research in, 31

## S

- Sacroiliac, *Mycobacterium intracellulare* and, 777-780
- Sacroiliitis, 663
  - HLA antigens in, 661
  - in Pima Indians, 791
- Salicylate-induced hepatic injury, 964-965
- Salicylates, liver enzymes and, 267-268
- Salmonella arthritis, 665
- Sarcoidosis, 660
- SATM, *see* Sodium aurothiomalate
- SCAT, *see* Sheep cell agglutination tests
- Schiff reaction, 1340
- Scleroderma
  - see also* Progressive systemic sclerosis
  - blood L lymphocytes in, 802-803
  - capillary microscopy in, 1368
  - collagen synthesis in, 816, 895
  - complement-fixing antinuclear antibody in, 857-860
  - eosinophilia and, 792
  - fibroblasts in, 817
  - mandibular bone erosion and, 1371
  - skin collagen biosynthesis in, 899-900
  - skin elasticity and colchicine in, 832
  - vinyl chloride and, 809
- Scleroderma Club, 36
- Scleroderma fibroblasts, connective tissue synthesis by, 891-900
- Sclerodermatous skin organ cultures, 804
- Sclerosis, pentazocine and, 925
- Sephadex G-200 fractions, in synovial fluid LDAC inhibition, 147
- Sephadex gel filtration, in LDAC studies, 143-144
- Septic arthritis, 65
- Serum dilution studies, in SLE, 74
- Serum immunoglobulins, in RA, 731-735
- Serum salicylate
  - in JRA, 115-118
  - in mixed leukocyte reaction, 537
- Sexual coupling, and chondromalacia patellae, 637-638
- SF, *see* Synovial fluid
- SGOT (serum glutamic oxaloacetic transaminase)
  - in C2 deficiency, 518-519
  - in Felty's syndrome, 153
  - serum salicylate and, 115-118
  - in Still's disease, 234
- SGPT (serum glutamic pyruvic transaminase)
  - in C2 deficiency, 518-519
  - serum salicylate and, 115-118
- Sheep cell agglutination tests, cyclophosphamide and, 569-570
- Shigella flexner* dysentery, 664
- Sjögren's syndrome
  - antibodies to nuclear antigens in, 574
  - antinuclear antibodies in, 712
  - autoantibody differentiation and characterization in, 216-222
  - cellular antigens reacting with, 218-219
  - complexity of, 216-217
  - counterimmunoelectrophoresis in, 578
  - defined, 216
  - dysproteinemia and, 1336
  - Felty's syndrome and, 150
  - HLA antigens in, 947
  - HLA-B8 and, 883-886
  - lymphocyte proliferation in, 811-812
  - nuclear ribonucleoprotein in, 576-577
  - organic brain syndrome and, 1334-1336
  - precipitins in, 218-220
  - rheumatoid factor in, 218
- Skeletal muscle abnormalities, in progressive systemic sclerosis, 807-808
- Skin
  - hyperextensibility of, 765
  - immune deposits in, in SLE, 1249-1254
- Skin capillary abnormalities, vinyl chloride and, 809
- Skin immunoreactants, in RA, 17
- Skin lesions
  - in C2 deficiency, 521
  - in extraarticular vasculitis, 18
- Skin vessels, immunofluorescence of, 18
- Skin-window test, in colchicine therapy, 620-621
- SLE, *see* Systemic lupus erythematosus
- SLE-like disease, C8 component in, 803
- Smallpox, arthritis and, 1317
- Smoking, maximal midexpiratory flow rates in, 624-625
- Sodium acetate extract, proteoglycans and, 210
- Sodium aurothiomalate, 907
  - lymphocytes and, 909
  - in RA, 802
- Sodium meclofenamate, 907
- Sodium warfarin therapy
  - in hemarthrosis, 98-101
  - quinidine and, 100
  - vitamin K and, 101
- Spine, ankylosing hyperostosis of, 818
- Spleen, gold levels in, 1368-1369
- Spleen cells, transfer of in NZB/W mice, 1353-1357
- Splenectomy, in Felty's syndrome, 150, 153
- Spondylitis, ankylosing, *see* Ankylosing spondylitis
- SS, *see* Sjögren's syndrome
- Staphylococcus albus*, 618
- Staphylococcus aureus*, endocarditis due to, 887
- Sternomanubrial joint disease, 1372-1373
- Steroid osteopenia, reduction of, 800
- Steroid pseudorheumatism, 1335
- Steroids, *see* Corticosteroids
- Still's disease, 232-241, 955
  - ankylosis in, 235, 240-241
  - hands and wrist in, 235-236
  - JRA and, 240
  - SGOT and SGPT levels in, 234
  - symptoms in, 233
- Streptococcal cell wall induced arthritis, 260-264
- Streptococcal peptidoglycan
  - immunochemistry of, 260-261
  - polysaccharide complex in, 261
- Subacute bacterial endocarditis, arthritis of, 813-814
- Superoxide radical, cartilage proteoglycan degradation by, 799
- Sydenham's chorea, possible cause of, 803
- Synovial cathepsin D, 738
- Synovial cells
  - in glycolysis or hyaluronic acid formation, 70
  - rabbit, *see* Rabbit synovial cells
- Synovial collagenase, in RA, 69

Synovial fibroblasts, hyaluronic acid from, 1315-1319

#### Synovial fluid

- CPPD crystals in, 93, 95
- enzymes in, 203
- human, *see* Human synovial fluid
- hydroxyapatite-like crystals in, 821
- immunologic tests for, 528
- in JRA, 161-166
- lactoferrin-to-lysozyme ratio in, 789
- LDAC and, 138, 142-149
- lymphoblasts and monocytes in, 745-747
- lymphokine-like substances in, 10
- MIF in, 10-13
- peripheral blood lymphocytes incubated from, 529
- proteoglycan breakdown products in, 772
- in relapsing polychondritis, 193
- in Whipple's disease, 820

#### Synovial fluid lymphocytes

- mitogenicity of for autologous peripheral blood lymphocytes, 530
- in peripheral blood lymphocyte transport, 523-530
- RA and, 523

Synovial fluid viscosity, measurement of, 1358-1361

#### Synovial membrane

- electron microscope studies of, 1-2
- joint destruction and, 737
- light microscopy studies of, 634
- rheumatoid, *see* Rheumatoid synovial membrane
- in RA, 581
- rosette forming cells in, 582-584
- samples of, 1-2
- in Whipple's disease, 820

Synovial small vessels, permeability of, 800

#### Synovial tissues

- cathepsin D secretion and localization in, 1295-1305
- nucleic acid hybridization in, 38-42
- T-lymphocyte predominance in, 555-561

#### Synovitis

- in degenerative joint disease, 813
- erosive, 256-264
- immune, *see* Immune synovitis
- plant thorn, 825
- in RA, 539-543

#### Synovium

- in experimental hemarthrosis, 60
- histologic appearance of, 1298
- plastic debris in, 793
- rheumatoid, *see* Rheumatoid synovium
- T and B cells in, 10-13

Systemic amyloidosis, humoral and cellular immune abnormalities in, 173-180

Systemic lupus erythematosus, 32, 75-76

- see also* Lupus erythematosus
- abnormal lymphocyte cell cycle kinetics in, 827-828
- absent factor II in, 79-81
- adrenal insufficiency in, 249-252
- allergy in, 669-673
- amyloidosis and, 249-252
- antibodies to DNA (nDNA) in, 867-870
- antibodies to nuclear antigens in, 574-575
- antibody avidity in, 806
- antibody binding of polyriboadenylic acid in, 705-709
- antibody to nuclear RNP detection in, 574
- anticomplementary activity of serum in, 76
- anti-DNA antibody in diagnosis of, 247
- antilymphocyte antibodies in, 821
- anti-nDNA antibodies in, 815, 867, 1253
- antinuclear antibody in, 1245
- antinuclear antibody in diagnosis of, 247
- anti-RNA antibody in, 1267
- ascites as major manifestation of, 782-785
- aspirin in, 155-160
- autoantibodies in, 88, 90

autologous mixed lymphocyte reactivity of blood cells in, 824-825

as best characterized human immune complex disease, 88

black vs white patients in, 130-131

B-lymphocyte activity in, 790

brain scan and cerebral radionuclide angiogram diagnosis

in, 826

C2 deficiency in, 517

calcinosis in, 247

case report in, 79

cell-mediated immunity in, 88, 1274-1275

circulating DNA in, 837

corticosteroid therapy in, 77, 79-81, 196-197

counterimmunoelectrophoresis in, 578

cutaneous vasculitis in, 814

dermatoglyphic study of, 83-86

discoid lesion and, 517-522

as disease of young women, 81

DNA-anti-DNA type, 669, 797

factor II defect in, 79-81

fibrinogen catabolism in, 195-198

fluorescent band skin test in, 792

hand deformity in, 248

hemorrhagic diathesis in, 79-80

hereditary C2 deficiency in, 517-522

histocompatibility antigens in, 129-131

HLA antigens in, 658-659

hydralazine therapy in, 122

IgG antilymphocyte antibodies in, 1261-1268

IgG galactose deficiency in, 813

as immune complex disease, 837

immune response in, 545-552

immune skin deposits in, 1249-1254

immunoblastic sarcoma and, 249-252

immunoglobulins in, 73, 670-671

immunologic studies in, 79-81

inflammatory disease in, 49

LDAC and, 142-149

low acetyl transferase activity in, 796

in lungs, 249-252

lupus anticoagulant in, 1244-1247

lupus band test in, 1249-1254

lymphocyte responsiveness in, 88-91, 805, 1271-1276

lymphocytotoxicity in, 100-103, 133-140, 817-818, 831,

844-849

lymphokine production in, 794

lysosomal enzyme reduction in, 73-77

Mexican-American vs Caucasian, 83

mitogen and antigen stimulation in, 89, 827-828

mitogen responses in, 547-550

mixed leukocyte cultures in, 546-549

monocyte identification in, 89

mononuclear cell isolation in, 89

naifold capillary microscopy in, 1370

nasal septum perforation in, 119-121

neoplasia in, 1256-1260

nephritis and, 49

oral contraceptives and, 602-603

organic brain syndrome and, 1336

peripheral blood cell suppressor function in, 791

persisting serologic abnormalities in, 837-843

phagocytosis reduction in, 73-77

PHA mitogens in, 89

PPD antigens in, 89

precipitating antibodies vs nuclear antigens in, 808

pulmonary hemorrhage in, 812

PWM in, 89

quantitation of blood L lymphocytes in, 802-803

radioimmunoassay in, 801

relatives affected by, 700-703

renal disease and, 195, 806

renal histologic abnormalities in, 824

serum autoantibodies in, 801



serum  $\beta$ 2-microglobulin and, 968  
 serum dilution in, 76  
 serum salicylate concentrations in, 115-116  
 SGOT level in, 158  
 T-cell dysfunction in, 88-89  
 thoracic duct drainage in, 814  
 thumb hyperextension and subluxation in, 247  
 twin studies in, 545-552  
 Type C RNA virus-related protein antigen in, 809-811, 816

## T

T-cell dysfunction, in SLE, 88  
 T-cell enumeration, in SLE, 89  
 T-cell function, in amyloidosis, 173  
 T-cell mitogen, 70  
 T cells, *see* T lymphocytes  
<sup>99m</sup>Tcnetium diphosphonate  
   periarticular joint concentration with, 610-611  
   periarticular uptake of, in psoriatics, 607-612  
 Temporal arteritis, non-giant cell, 812  
 Tenosynovitis, Still's disease and, 234  
 Thermal denaturation  
   histidine concentration in, 599  
   of human gamma globulin, 593-599  
 Thomas Report, 31  
 Thrombocytosis, in RA, 793  
 Thrombophlebitis, 1335  
 Thymic factors, in NZB/W mice, 862-865  
 Thymidine, tritiated, 907-916  
<sup>3</sup>H-Thymidine, in articular cartilage metabolic changes, 199-204  
 Thymocytes, autoimmunity suppression with, 345-347  
 Thymosin  
   in amyloidosis, 180  
   in NZB/W mice, 862-865  
 T lymphocytes  
   in amyloidosis, 175-176  
   and familial Mediterranean fever, 618  
   lymphokines and, 10  
   macrophages and, 8-10  
   predominance of in RA, 555-561  
   in rheumatoid synovitis, 8-13, 557-560  
   serum antibodies against, 1328-1332  
 Tobacco smoking, in obstructive pulmonary disease, 623-626  
 Tolmetin, aspirin and, in JRA, 807  
 "Total hand" infection, long-term effects of, 800  
 Total hemolytic component, in JRA, 161-166  
 Transaminase concentrations, in JRA, 115-118  
   *see also* SGOT (serum glutamic oxaloacetic transaminase)  
 Transitional areas  
   fibroblast degeneration in, 6  
   lymphoid cell-macrophage contact in, 6  
   perivascular cells in, 13  
   in rheumatoid synovitis, 5-8  
   T and B lymphocytes in, 8-10  
 Trapezioscapoid arthropathy, 833  
 Triton X-100, 927, 931  
 Trypan blue cytotoxicity test, 224-227  
 Tubuloreticular structures, in SLE lymphocyte twin studies, 546, 551-552  
 Twin studies  
   antigens in, 545  
   in SLE, 545-552  
   tubuloreticular structures in, 546, 551-552

## U

Ulcerative colitis, 660, 662  
 HLA antigens and, 662  
 Ultrasound B-scanning, 651

Uniform Database for Rheumatic Diseases, 645-647  
 Urate, tubular transport of, 811  
 Urethritis, Reiter's disease following, 664  
 Uric acid excretion, benzbromarone and, 183  
 Uricosuric drug, benzbromarone as, 183  
 Uronic acid  
   loss of in arthritic cartilage, 211  
   recovery of, 212  
 Uveitis, anterior nongranulomatous, 539-543

## V

Vaccinia  
   arthritis and, 1317  
   azathioprine and, 270  
 Varicella, arthritis and, 1317  
 Varicella-zoster virus antigens, immune response to, 1271, 1274  
 Vasculitis  
   cryoproteins in, 829  
   development of, 19  
   extraarticular, 18  
   immune deposits in, 19  
   in RA, 15-19, 1237, 1241  
   rheumatoid, 15-19, 950-951  
   in rheumatoid synovitis, 18  
   skin immunoreactions and, 17  
   skin lesions in, 15  
 Ventricular tachycardia, 1373-1374  
 Venulitis, cutaneous necrotizing, 945-949  
 Veracruz period, pre-Columbian representation of Heberden's nodes in, 125-126  
 Vinyl chloride, skin capillary abnormalities and, 809  
 Vinyl chloride acro-osteolysis, resorption of mandible in, 971  
 Viral hepatitis  
   arthritis and, 1317  
   drug abuse in, 923  
 Viral RNA-directed DNA polymerase, 816  
 Virus antigens  
   lymphocyte response to, in SLE, 1271-1276  
   prednisolone and, 1274  
 Viscosity increment  
   histidine and, 595-596  
   of human gamma globulins, 595-596  
 Vitamin D, in steroid osteopenia reduction, 800  
 Vitamin K therapy, in hemarthrosis, 101

## W

Warfarin therapy, 98-101  
 Wax D, adjuvanticity of, 259  
 Wegener's granulomatosis, nasal septum perforation in, 119-121  
 Whipple's disease, 820  
 White blood cell pipette, in synovial fluid measurement, 1358-1361  
 Women  
   rheumatoid factor in, 602-606  
   SLE in, 81  
 Wrist  
   in RA, 828, 939-944  
   in Still's disease, 235-240  
   swelling of in ankylosing spondylitis, 112-113

## Y

Yersinia arthritis, 31-32  
 Yersinia enterocolitica, 664-665

## Z

Zymosan, uptake of, 73



